Author: "F. Atzeni" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"F. Atzeni"' showing total 613 results

Start Over Author "F. Atzeni"

613 results on '"F. Atzeni"'

51. CARDIOVASCULAR RISK ASSESSMENT IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES -ITALIAN SURVEY

Author: Fornaro, Marco, Spinelli, Francesca Romana, Cacciapaglia, Fabio, F. Atzeni, Erre, Gian Luca, Manfredi, Andreina, Bocci, Elena Bartoloni, Piga, Matteo, Garifallia Sakellariou, Viapiana, Ombretta, and Gremese, Elisa
Published: 2020
Full Text: View/download PDF

52. OP0006 Influence of autonomic nervous system dysfunction in the genesis of sleep disorders in fibromyalgia patients

Author: M Rizzi, D Radovanovic, P Santus, A Airoldi, F Frassanito, S Vanni, A Cristiano, R Casale, R Furlan, F Atzeni, and P Sarzi-Puttini
Subjects: 030203 arthritis & rheumatology, Sympathetic nervous system, medicine.diagnostic_test, business.industry, Sleep Wake Disorders, Polysomnography, medicine.disease, Sleep in non-human animals, 03 medical and health sciences, Autonomic nervous system, 0302 clinical medicine, medicine.anatomical_structure, Blood pressure, Fibromyalgia, Anesthesia, Heart rate, medicine, business, 030217 neurology & neurosurgery
Abstract: Objectives Fibromyalgia (FM) is characterised by chronic musculoskeletal pain, autonomic nervous system (ANS) dysfunction, and disturbed sleep. The aim of this study was to evaluate the influence of ANS dysfunction on the genesis of sleep disorders. Methods Fifty female FM patients and 45 healthy subjects matched for age, gender and body mass index underwent a clinical, polysomnographic and autonomic profile evaluation at rest and during a tilt test in order to determine muscle sympathetic nerve activity (MSNA), plasma catecholamine levels, and the spectral indices of cardiac sympathetic (LFRR) and vagal (HFRR) modulation computed by means of the spectrum analysis of RR during sleep. Results The FM patients had a higher heart rate (HR), more MSNA and a higher LF/HF ratio, and lower HFRR values at rest (p Conclusions Our findings seem to show that sleep causes the same effects as a stressful test in FM patients. A vicious circle is created during sleep: pain increases sympathetic cardiovascular activation and reduces sleep efficiency, thus causing lighter sleep, a higher CAP rate, more arousals, a higher PLMI, and increasing the occurrence of PB, which gives rise to abnormal cardiovascular neural control and exaggerated pain sensitivity.
Published: 2017
Full Text: View/download PDF

53. Cardiac Imaging Techniques in Systemic Autoimmune Diseases

Author: L. Gianturco, P. Sarzi-Puttini, M. Porcu, Maurizio Turiel, Marco Corda, and F. Atzeni
Subjects: medicine.medical_specialty, education.field_of_study, Younger age, business.industry, Population, Disease, medicine.disease, Asymptomatic, Primary antiphospholipid syndrome, Internal medicine, Rheumatoid arthritis, mental disorders, medicine, Cardiac Imaging Techniques, medicine.symptom, skin and connective tissue diseases, education, business, Systemic vasculitis
Abstract: The most frequent systemic autoimmune diseases (SADs) are rheumatoid arthritis, systemic lupus erythematosus, primary antiphospholipid syndrome, systemic sclerosis, and systemic vasculitis. Patients with SADs are at risk of increased cardiovascular (CV) morbidity and mortality that is mainly due to enhanced atherosclerosis and only partially related to traditional CV risk factors. In particular, the CV disease occurs at a younger age than in the general population, and often remains asymptomatic at least in the early stages.
Published: 2017
Full Text: View/download PDF

54. Cardiovascular Involvement in Psoriatic Arthritis

Author: F. Caso, Ignazio Francesco Masala, P. Sarzi-Puttini, F. Atzeni, Atzeni, F., Caso, F., Masala, I. F., and Sarzi-puttini, P.
Subjects: Necrosis, Tumor necrosis factor, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Antirheumatic drug, Disease, Proinflammatory cytokine, 03 medical and health sciences, Psoriatic arthritis, 0302 clinical medicine, Immunology and Allergy, Medicine, 030212 general & internal medicine, Mortality, 030203 arthritis & rheumatology, business.industry, Mechanism (biology), Psoriatic arthriti, Immunosuppression, medicine.disease, Atherosclerosi, Immunology, Cardiovascular involvement, Tumor necrosis factor alpha, Inflammatory pathways, medicine.symptom, business
Abstract: Psoriatic arthritis is a chronic inflammatory condition in which unbalanced inflammatory pathways act as key drivers of a wide range of articular and extraarticular manifestations. It is associated with a high prevalence of cardiovascular (CV) disease and risk factors. The precise pathogenetic mechanism of CV involvement has still to be clarified, but certain inflammatory cytokines play a key role in the atherosclerotic process. Studies have shown the potentially beneficial role of disease-modifying antirheumatic drug–induced immunosuppression and also anti–tumor necrosis factor drugs on CV diseases.
Published: 2017
Full Text: View/download PDF

55. New Cardiac Imaging Tools and Invasive Techniques in Systemic Autoimmune Diseases (Part II)

Author: Maurizio Turiel, L. Gianturco, M. Porcu, Marco Corda, F. Atzeni, and Piercarlo Sarzi-Puttini
Subjects: medicine.medical_specialty, Ejection fraction, Myocarditis, Hypereosinophilic syndrome, business.industry, Pericardial fluid, medicine.disease, Coronary artery disease, Mixed connective tissue disease, Internal medicine, medicine, Cardiology, Myocardial infarction, business, Cardiac imaging
Abstract: Systemic inflammatory diseases are associated with an increase in cardiovascular (CV) morbidity and mortality. CV involvement in systemic inflammatory diseases is highly heterogeneous, with manifestations affecting different heart structures. New instruments now allow an early diagnosis and prompt treatment. Over the last few years, Cardiac MRI has emerged as a noninvasive means of accurately and reproducibly assessing myocardial anatomy and function and has become the gold standard for measuring the ejection fraction, and left and right ventricular volumes. It can reveal myocardial lesions in patients with mixed connective tissue disease (CTD) and cardiac symptoms, including myocardial infarction, inflammation, and widespread subendocardial fibrosis and perfusion defects, which require further cardiac investigation and/or treatment. Computed tomography (CT) has evolved into such a potent means of diagnosis. It has become very important for cardiologists because it is widely available, easy to use, noninvasive, and highly sensitive in detecting coronary artery disease, and evaluating pericardial disease, pericardial fluid, and pericardial neoplasms. Radiation doses are a matter of concern and special measures need to be taken to avoid unnecessarily high doses when CT is used for coronary artery imaging. Pulmonary arterial hypertension (PAH) is one of the major complications of CTDs such as systemic sclerosis, systemic lupus erythematosus, and mixed CTD. Right heart catheterization is a fundamental means of confirming a diagnosis of PAH and assessing a risk that, when performed at dedicated centers, is associated with low morbidity and mortality rates. Myocarditis is an inflammatory disease of the myocardium caused by various infectious and noninfectious triggers. Systemic autoimmune diseases such as Churg–Strauss syndrome or hypereosinophilic syndrome (Loeffler's disease) can be associated with eosinophilic myocarditis. In the case of cardiac sarcoidosis and giant cell myocarditis, which are rare causes of inflammatory myocardial disease, early diagnosis and treatment significantly improve prognosis. The diagnostic gold standard is still an endomyocardial biopsy.
Published: 2017
Full Text: View/download PDF

56. Poster Session 4: Friday 9 December 2011, 14:00-18:00 * Location: Poster Area

Author: M. Wang, G. Yan, W. Yue, C. Siu, H. Tse, A. Perperidis, D. Cusack, A. White, T. Macgillivray, W. Mcdicken, T. Anderson, V. Ryabov, V. Shurupov, T. Suslova, V. Markov, N. Elmstedt, K. Ferm Widlund, B. Lind, L.-A. Brodin, M. Westgren, F. Mantovani, A. Barbieri, F. Bursi, C. Valenti, M. Quaglia, M. Modena, D. Peluso, D. Muraru, L. Dal Bianco, M. Beraldo, E. Solda', M. Tuveri, U. Cucchini, A. Al Mamary, L. Badano, S. Iliceto, A. Goncalves, C. Almeria, P. Marcos-Alberca, G. Feltes, R. Hernandez-Antolin, H. Rodriguez, L. Maroto, J. Silva Cardoso, C. Macaya, J. Zamorano, S. Squarciotta, F. Innocenti, A. Guzzo, S. Bianchi, D. Lazzeretti, E. De Villa, S. Vicidomini, B. Del Taglia, C. Donnini, R. Pini, C. Mennie, A. M. Salmasi, V. Kutyifa, V. Nagy, E. Edes, A. Apor, B. Merkely, S. Nyrnes, L. Lovstakken, H. Torp, B. Haugen, K. Said, A. Shehata, Z. Ashour, S. El-Tobgy, M. Cameli, E. Bigio, M. Lisi, F. Righini, F. Franchi, S. Scolletta, S. Mondillo, E. Gayat, L. Weinert, C. Yodwut, V. Mor-Avi, R. Lang, N. Hrynchyshyn, N. Kachenoura, B. Diebold, R. Khedim, M. Senesi, A. Redheuil, E. Mousseaux, L. Perdrix, S. Yurdakul, V. Erdemir, Y. Tayyareci, K. Memic, O. Yildirimturk, V. Aytekin, M. Gurel, S. Aytekin, L. Gargani, C. Fernandez Cimadevilla, S. La Falce, P. Landi, E. Picano, R. Sicari, M. K. Smedsrud, J. Gravning, C. Eek, L. Morkrid, H. Skulstad, L. Aaberge, B. Bendz, J. Kjekshus, T. Edvardsen, G. Bajraktari, V. Hyseni, B. Morina, A. Batalli, R. Tafarshiku, R. Olloni, M. Henein, O. Mjolstad, S. Snare, L. Folkvord, F. Helland, O. Haraldseth, A. Grimsmo, M. Berry, O. Zaghden, J. Nahum, L. Macron, O. Lairez, T. Damy, A. Bensaid, J. Dubois Rande, P. Gueret, P. Lim, N. Nciri, Z. Issaoui, C. Tlili, I. Wanes, H. Foudhil, F. Dachraoui, J. Grapsa, D. Dawson, P. Nihoyannopoulos, L. Gianturco, M. Turiel, F. Atzeni, P. Sarzi-Puttini, D. Stella, L. Donato, L. Tomasoni, P. Jung, M. Mueller, T. Huber, G. Sevilmis, F. Kroetz, H. Sohn, V. Panoulas, A. Bratsas, R. Raso, G. Tartarisco, G. Pioggia, P. Gargiulo, M. Petretta, A. Cuocolo, M. Prastaro, C. D'amore, E. Vassallo, G. Savarese, C. Marciano, S. Paolillo, P. Perrone Filardi, C. Aggeli, I. Felekos, G. Roussakis, E. Poulidakis, P. Pietri, K. Toutouzas, C. Stefanadis, A. Kaladaridis, I. Skaltsiotis, G. Kottis, D. Bramos, D. Takos, I. Matthaios, I. Agrios, E. Papadopoulou, S. Moulopoulos, S. Toumanidis, P. Carrilho-Ferreira, N. Cortez-Dias, C. Jorge, D. Silva, J. Silva Marques, R. Placido, L. Santos, S. Ribeiro, M. Fiuza, F. Pinto, V. Stoickov, S. Ilic, M. Deljanin Ilic, W. Kim, J. Woo, J. Bae, K. Kim, M. Descalzo, J. Rodriguez, S. Moral, I. Otaegui, P. Mahia, L. Garcia Del Blanco, T. Gonzalez Alujas, J. Figueras, A. Evangelista, D. Garcia-Dorado, M. Takeuchi, K. Kaku, K. Otani, M. Iwataki, H. Kuwaki, N. Haruki, H. Yoshitani, Y. Otsuji, M. Kukucka, M. Pasic, A. Unbehaun, S. Dreysse, A. Mladenow, H. Kuppe, R. Hetzer, N. Rajamannan, A. Tanrikulu, L. Kristiansson, S. Gustafsson, K. Lindmark, M. Y. Henein, C. Evdoridis, P. Stougiannos, M. Thomopoulos, M. Fosteris, P. Spanos, G. Sionis, D. Giatsios, A. Paschalis, C. Sakellaris, A. Trikas, Z. Y. Yong, K. Boerlage-Van Dijk, K. Koch, M. Vis, B. Bouma, J. Piek, J. Baan, L. Abid, Z. Frikha, K. Makni, N. Maazoun, D. Abid, M. Hentati, S. Kammoun, P. Barbier, A. Staron, C. Cefalu', G. Berna, P. Gripari, D. Andreini, G. Pontone, M. Pepi, L. Ring, B. Rana, S. Ho, F. Wells, A. Dogan, O. Karaca, G. Guler, E. Guler, H. Gunes, E. Alizade, H. Agus, G. Gol, O. Esen, A. Esen, M. Turkmen, E. Agricola, G. Ingallina, M. Ancona, S. Maggio, M. Slavich, V. Tufaro, M. Oppizzi, A. Margonato, C. Orsborne, B. Irwin, K. Pearce, S. Ray, C. Garcia Alonso, N. Vallejo, C. Labata, J. Lopez Ayerbe, A. Teis, E. Ferrer, R. Nunez Aragon, F. Gual, M. Pedro Botet, A. Bayes Genis, C. M. Santos, M. Carvalho, M. Andrade, H. Dores, S. Madeira, G. Cardoso, A. Ventosa, C. Aguiar, R. Ribeiras, M. Mendes, M. Petrovic, G. Milasinovic, B. Vujisic-Tesic, I. Nedeljkovic, D. Zamaklar-Trifunovic, I. Petrovic, G. Draganic, M. Banovic, M. Boricic, H. Villarraga, C. Molini-Griggs Bs, P. Silen-Rivera Bs, B. Payne Mph Ms, Y. Koshino Md Phd, J. Hsiao Md, V. Monivas Palomero, S. Mingo Santos, C. Mitroi, I. Garcia Lunar, P. Garcia Pavia, V. Castro Urda, J. Toquero, J. Gonzalez Mirelis, M. Cavero Gibanel, I. Fernandez Lozano, Z. Oko-Sarnowska, H. Wachowiak-Baszynska, A. Katarzynska-Szymanska, O. Trojnarska, S. Grajek, D. Bellavia, P. Pellikka, A. Dispenzieri, J. K. Oh, V. Polizzi, F. Pitrolo, F. Musumeci, F. Miller, R. Ancona, S. Comenale Pinto, P. Caso, S. Severino, C. Cavallaro, F. Vecchione, A. D'onofrio, R. Calabro', A. M. Maceira Gonzalez, C. Ripoll, J. Cosin-Sales, B. Igual, J. Salazar, V. Belloch, J. Cosin-Aguilar, B. Pinamonti, A. Iorio, M. Bobbo, M. Merlo, G. Barbati, L. Massa, G. Faganello, A. Di Lenarda, G. F. Sinagra, T. Ishizu, Y. Seo, M. Enomoto, Y. Kameda, N. Ishibashi, M. Inoue, K. Aonuma, A. Saleh, A. Matsumori, H. Negm, H. Fouad, A. Onsy, E. Hamodraka, I. Paraskevaidis, M. Kallistratos, V. Lezos, T. Zamfir, C. Manetos, D. Mavropoulos, L. Poulimenos, D. Kremastinos, A. Manolis, R. Citro, F. Rigo, Q. Ciampi, M. Patella, G. Provenza, C. Zito, E. Tagliamonte, F. Rotondi, F. Silvestri, E. Bossone, P. Beltran Correas, C. Gutierrez Landaluce, M. Gomez Bueno, J. Segovia Cubero, C. Beladan, F. Matei, B. Popescu, A. Calin, M. Rosca, A. Boanta, R. Enache, O. Savu, C. Usurelu, C. Ginghina, A. O. Ciobanu, R. Dulgheru, S. Magda, R. Dragoi, M. Florescu, D. Vinereanu, S. Robalo Martins, C. Calisto, S. Goncalves, I. Barrigoto, J. Carvalho De Sousa, A. Almeida, A. Nunes Diogo, L. Sargento, M. Satendra, C. Sousa, N. Lousada, R. Palma Reis, V. Schiano Lomoriello, R. Esposito, A. Santoro, R. Raia, P. Schiattarella, E. Dores, M. Galderisi, N. Mansencal, V. Caille, A. Dupland, S. Perrot, K. Bouferrache, A. Vieillard-Baron, R. Jouffroy, P. Moceri, E. Liodakis, M. Gatzoulis, W. Li, K. Dimopoulos, M. Sadron, P. E. Seguela, B. Arnaudis, Y. Dulac, T. Cognet, P. Acar, Y. Shiina, H. Uemura, K. Kupczynska, J. Kasprzak, B. Michalski, P. Lipiec, V. Carvalho, A. M. G. Almeida, C. David, J. Marques, P. Ferreira, M. Amaro, P. Costa, A. Diogo, V. Tritakis, I. Ikonomidis, J. Lekakis, S. Tzortzis, N. Kadoglou, I. Papadakis, P. Trivilou, C. Koukoulis, M. Anastasiou-Nana, T. Bombardini, S. Gherardi, G. Arpesella, M. Maccherini, W. Serra, G. Magnani, R. Del Bene, E. Pasanisi, U. Startari, L. Panchetti, A. Rossi, M. Piacenti, M. Morales, I. El Hajjaji, R. El Mahmoud, F. Digne, O. Dubourg, G. Agoston, A. Moreo, L. Pratali, A. Moggi Pignone, A. Pavellini, M. Doveri, F. Musca, A. Varga, F. Faita, S. Rimoldi, C. Sartori, Y. Alleman, C. Salinas Salmon, M. Villena, U. Scherrer, R. Baptista, S. Serra, G. Castro, R. Martins, M. Salvador, P. Monteiro, J. Silva, L. Szudi, A. Temesvary, B. Fekete, I. Kassai, L. Szekely, S. S. Abdel Moneim, M. Martinez, S. Mankad, M. Bernier, A. Dhoble, K. Chandrasekaran, J. Oh, S. Mulvagh, G. R. Hong, J. Y. Kim, S. C. Lee, S. H. Choi, I. S. Sohn, H. S. Seo, J. H. Choi, K. I. Cho, S. J. Yoon, S. J. Lim, P. Wejner-Mik, J. Kusmierek, A. Plachcinska, R. Szuminski, S. Stoebe, A. Tarr, T. Trache, A. Hagendorff, C. Jenkins, H. Kuhl, H. Nesser, T. Marwick, A. Franke, J. Niel, L. Sugeng, S. Soderberg, P. Lindqvist, J. Necas, S. Kovalova, S. K. Saha, A. Kiotsekoglou, R. Toole, S. Govind, A. Gopal, M.-S. Amzulescu, A. Florian, J. Bogaert, S. Janssens, J. Voigt, V. Parisi, M. Losi, L. Parrella, C. Contaldi, E. Chiacchio, A. Caputi, A. Scatteia, A. Buonauro, S. Betocchi, R. Rimbas, S. Mihaila, M. Caputo, R. Navarri, P. Innelli, R. Urselli, E. Capati, P. Ballo, F. Furiozzi, R. Favilli, R. Lindquist, A. Miller, C. Reece, P. O'leary, F. Cetta, B. W. Eidem, M. Cikes, H. Gasparovic, B. Bijnens, V. Velagic, T. Kopjar, B. Biocina, D. Milicic, A. Ta-Shma, A. Nir, Z. Perles, S. Gavri, J. Golender, A. Rein, G. Pinnacchio, L. Barone, I. Battipaglia, A. Cosenza, L. Marinaccio, I. Coviello, G. Scalone, A. Sestito, G. Lanza, F. Crea, S. Cakal, E. Eroglu, B. Ozkan, S. Kulahcioglu, M. Bulut, A. Koyuncu, G. Acar, G. Alici, C. Dundar, F. Labombarda, E. Zangl, A. Pellissier, D. Bougle, P. Maragnes, P. Milliez, E. Saloux, S. Lagoudakou, E. Gialafos, A. Tsokanis, A. Nagy, T. Kovats, H. Vago, A. Toth, B. Sax, A. Kovacs, M. F. Elnoamany, H. Badran, I. Abdelfattah, T. Khalil, M. Salama, T. Butz, C. Taubenberger, F. Thangarajah, A. Meissner, M. Van Bracht, M. Prull, H. Yeni, G. Plehn, H. Trappe, R. Rydman, D. Bone, M. Alam, K. Caidahl, F. Larsen, Z. Gasior, Z. Tabor, P. Sengupta, D. Liu, M. Niemann, K. Hu, S. Herrmann, S. Stoerk, C. Morbach, S. Knop, W. Voelker, G. Ertl, F. Weidemann, P. Cawley, C. Hamilton-Craig, L. Mitsumori, J. Maki, C. Otto, M. Astrom Aneq, E. Nylander, T. Ebbers, J. Engvall, P. Arvanitis, F. Flachskampf, O. Duvernoy, F. De Torres Alba, S. Valbuena Lopez, G. Guzman Martinez, J. Gomez De Diego, J. Rey Blas, E. Armada Romero, E. Lopez De Sa, M. Moreno Yanguela, J. Lopez Sendon, N. Trikalinos, G. Siasos, A. Aggeli, A. Tomaszewski, A. Kutarski, M. Tomaszewski, O. Vriz, C. Driussi, M. Bettio, D. Pavan, F. Antonini Canterin, A. Doltra Magarolas, J. Fernandez-Armenta, E. Silva, N. Solanes, M. Rigol, A. Barcelo, L. Mont, A. Berruezo, J. Brugada, M. Sitges, F. L. Ciciarello, S. Mandolesi, F. Fedele, L. Agati, A. Marceca, S. Rhee, S. Shin, S. Kim, K. Yun, N. Yoo, N. Kim, S. Oh, J. Jeong, and N. Alabdulkarim
Subjects: education.field_of_study, medicine.medical_specialty, business.industry, Multiple sclerosis, Population, Hemodynamics, General Medicine, Cerebro, medicine.disease, Internal medicine, Cardiology, Medicine, Radiology, Nuclear Medicine and imaging, Cardiology and Cardiovascular Medicine, education, business
Published: 2011
Full Text: View/download PDF

57. Poster Session 2: Thursday 8 December 2011, 14:00-18:00 * Location: Poster Area

Author: X. Luo, F. Fang, J. Sun, J. Xie, A. Lee, Q. Zhang, C. Yu, O. Breithardt, S. Schiessl, M. Schmid, M. Seltmann, L. Klinghammer, C. Zeissler, M. Kuechle, W. Daniel, M. Ege, U. Guray, Y. Guray, B. Demirkan, H. Kisacik, S.-E. Kim, J.-Y. Hong, J.-H. Lee, D.-G. Park, K.-R. Han, D.-J. Oh, O. Tufekcioglu, D. C. Cozma, C. Mornos, A. Ionac, L. Petrescu, C. Tutuianu, S. I. Dragulescu, L. Guimaraes, G. Tavares, A. Rodrigues, C. Nagamatsu, C. Fischer, M. Vieira, W. Oliveira, T. Wilberg, A. Cordovil, S. Morhy, D. Muraru, M. Peluso, L. Dal Bianco, M. Beraldo, E. Solda', M. Tuveri, U. Cucchini, A. Al Mamary, L. Badano, S. Iliceto, A. Pizzuti, B. Mabritto, C. Derosa, A. Tomasello, M. Rovere, I. Parrini, M. Conte, N. Lareva, A. Govorin, R. Cooper, J. Sharif, J. D. Somauroo, J. D. Hung, V. Porcelli, R. Skevington, A. Shahzad, S. Scott, P. Lindqvist, S. Soderberg, M. Gonzalez, E. Tossavainen, M. Henein, N. Nciri, H. Saad, S. Nawas, A. Ali, A. Youssufzay, A. Safi, S. Faruk, S. Yurdakul, V. Erdemir, Y. Tayyareci, O. Yildirimturk, K. Memic, V. Aytekin, M. Gurel, S. Aytekin, M. Przewlocka-Kosmala, M. Cielecka-Prynda, A. Mysiak, W. Kosmala, S. Pescariu, D. Cozma, A. Mornos, S. Dragulescu, N. Maurea, C. G. Tocchetti, C. Coppola, C. Quintavalle, D. Rea, A. Barbieri, G. Piscopo, C. Arra, G. Condorelli, R. Iaffaioli, H. Dalen, A. Thorstensen, H. Moelmen, H. Torp, A. Stoylen, D. Augustine, C. Basagiannis, J. Suttie, P. Cox, R. Aitzaz, A. Lewandowski, M. Lazdam, C. Holloway, H. Becher, P. Leeson, S. Radovanovic, A. Djokovic, B. Todic, M. Zdravkovic, M. Zaja-Simic, S. Banicevic, D. Lisulov-Popovic, M. Krotin, J. Grapsa, D. O'regan, D. Dawson, G. Durighel, L. Howard, J. Gibbs, P. Nihoyannopoulos, C. Tulunay Kaya, M. Kilickap, H. Kurklu, N. Ozbek, C. Koca, V. Kozluca, K. Esenboga, C. Erol, B. Kusmierczyk-Droszcz, E. Kowalik, J. Niewiadomska, P. Hoffman, M. Satendra, L. Sargento, S. Lopes, S. Longo, N. Lousada, R. Palma Reis, P. Chillo, A. Rieck, J. Lwakatare, J. Lutale, E. Gerdts, S. Bonapace, G. Molon, G. Targher, A. Rossi, L. Lanzoni, G. Canali, E. Campopiano, L. Zenari, L. Bertolini, E. Barbieri, K. Hristova, L. Vladiomirova-Kitova, T. Katova, F. Nikolov, P. Nikolov, S. Georgieva, I. Simova, V. Kostova, V. A. Kuznetsov, D. V. Krinochkin, P. A. Chandraratna, Y. A. Pak, E. H. Zakharova, A. V. Plusnin, M. V. Semukhin, E. A. Gorbatenko, E. I. Yaroslavskaya, G. Bedetti, L. Gargani, M. Scalese, C. Pizzi, R. Sicari, E. Picano, M. Reali, E. Canali, S. Cimino, M. Francone, M. Mancone, R. Scardala, F. Boccalini, Y. Hiramoto, A. Frustaci, L. Agati, K. Savino, A. Lilli, E. Bordoni, C. Riccini, G. Ambrosio, D. Silva, N. Cortez-Dias, P. Carrilho-Ferreira, C. Jorge, J. Silva-Marques, A. Magalhaes, L. Santos, S. Ribeiro, F. Pinto, A. Nunes Diogo, E. Kinova, N. Zlatareva, A. Goudev, C. Bonanad, M. Lopez-Lereu, J. Monmeneu, V. Bodi, J. Sanchis, J. Nunez, F. Chaustre, A. Llacer, D. Ermacora, D. Peluso, M. Di Lazzari, P. Meimoun, F. Elmkies, T. Benali, J. Boulanger, H. Zemir, J. Clerc, A. Luycx-Bore, M. S. Velasco Del Castillo, A. Cacicedo Fernandez De Bobadilla, J. Onaindia Gandarias, M. Telleria Arrieta, G. Zugazabeitia Irazabal, O. Quintana Raczka, I. Rodriguez Sanchez, A. Romero Pereiro, E. Laraudogoitia Zaldumbide, I. Lekuona Goya, B. Bonello, E. El Louali, V. Fouilloux, I. Kammache, C. Ovaert, B. Kreitmann, A. Fraisse, R. Migliore, M. Adaniya, M. Barranco, G. Miramont, H. Tamagusuku, A. Alassar, R. Sharma, A. Marciniak, O. Valencia, N. Abdulkareem, M. Jahangiri, N. Jander, R. Kienzle, C. Gohlke-Baerwolf, H. Gohlke, F.-J. Neumann, J. Minners, S. Valbuena, F. De Torres, T. Lopez, J. J. Gomez, G. Guzman, F. Dominguez, E. Refoyo, M. Moreno, J. L. Lopez-Sendon, R. Ancona, S. Comenale Pinto, P. Caso, G. Di Salvo, S. Severino, M. Cavallaro, R. Calabro, R. Enache, R. Piazza, A. Roman-Pognuz, B. Popescu, A. Calin, C. Beladan, F. Purcarea, G. Nicolosi, C. Ginghina, O. Savu, M. Rosca, R. Jurcut, M. Serban, L. Dorobantu, E. Donal, S. Mascle, C. Thebault, D. Veillard, H. Hamonic, A. Leguerrier, H. Corbineau, B. A. Popa, M. Diena, A. Bogdan, D. Benea, G. Lanzillo, V. Casati, E. Novelli, A. Popa, G. Cerin, F. Gual Capllonch, A. Teis, J. Lopez Ayerbe, E. Ferrer, N. Vallejo, E. Gomez Denia, A. Bayes Genis, S. Spethmann, S. Schattke, G. Baldenhofer, V. Stangl, M. Laule, G. Baumann, K. Stangl, F. Knebel, C. Labata, C. Garcia Alonso, F. Gual, R. Nunez Aragon, C. Sousa, A. I. Vasile, M. Dorobantu, C. Iorgulescu, S. Bogdan, D. Constantinescu, C. Caldararu, O. Tautu, R. Vatasescu, H. Badran, M. F. Elnoamany, M. Ayad, A. Elshereef, A. Farhan, Y. Nassar, M. Yacoub, J. Costabel, G. Avegliano, P. Elissamburu, J. Thierer, F. Castro, M. Huguet, A. Frangi, R. Ronderos, C. Prinz, F. Van Buuren, L. Faber, T. Bitter, N. Bogunovic, W. Burchert, D. Horstkotte, J. D. Kasprzak, A. Smialowski, T. Rudzinski, P. Lipiec, M. Krzeminska-Pakula, K. Wierzbowska-Drabik, E. Trzos, M. Kurpesa, H. Motoki, M. Hana, T. Marwick, K. Allan, M. Vazquez-Alvarez, C. Medrano Lopez, S. Granja Da Silva, C. Marcos, A. Rodriguez-Ogando, M. Alvarez, M. Camino, M. Centeno, E. Maroto, G. Feltes Guzman, V. Serra Tomas, O. Acevedo, A. Calli, M. Barba, G. Pintos, V. Valverde, J. Zamorano Gomez, M. Marchel, J. Kochanowski, R. Piatkowski, A. Madej, K. Filipiak, I. Hausmanowa-Petrusewicz, G. Opolski, E. Malev, E. Zemtsovsky, S. Reeva, E. Timofeev, A. Pshepiy, S. Mihaila, R. Rimbas, R. Mincu, R. Dulgheru, R. Mihaila, C. Badiu, M. Cinteza, D. Vinereanu, E. Lira, D. Lebihan, C. Monaco, M. Ruiz Ortiz, D. Mesa, M. Delgado, E. Romo, M. Pena, M. Puentes, M. Santisteban, A. Lopez Granados, J. Arizon Del Prado, J. Suarez De Lezo, W.-C. Tsai, J.-Y. Shih, T.-S. Huang, Y.-W. Liu, Y.-Y. Huang, L.-M. Tsai, E. Cho, K. Choi, B. Kwon, D. Kim, S. Jang, C. Park, H. Jung, H. Jeon, H. Youn, J. Kim, A. E. Rieck, D. Cramariuc, M. Lonnebakken, B. Lund, P. Moceri, D. Doyen, P. Cerboni, E. Ferrari, W. Li, S. Goncalves, G. Vinhais De Sousa, A. G. Almeida, C. Hernandez Garcia, A. De La Rosa Hernandez, E. Arroyo Ucar, P. Jorge Perez, A. Barragan Acea, J. Lacalzada Almeida, J. Jimenez Rivera, A. Duque Garcia, I. Laynez Cerdena, O. Arhipov, A. N. Sumin, L. Campens, M. Renard, B. Trachet, P. Segers, A. De Paepe, J. De Backer, J. A. Purvis, D. Sharma, S. M. Hughes, D. Marek, D. Vindis, E. Kocianova, M. Taborsky, H. Yoon, K. Kim, Y. Ahn, M. Chung, J. Cho, J. Kang, W. Rha, O. Ozcan, D. Sezgin Ozcan, B. Candemir, M. Aras, I. Dincer, R. Atak, L. Gianturco, M. Turiel, F. Atzeni, L. Tomasoni, E. Bruschi, O. Epis, P. Sarzi-Puttini, C. Aggeli, E. Poulidakis, I. Felekos, S. Sideris, P. Dilaveris, K. Gatzoulis, C. Stefanadis, N. Roszczyk, M. Sobczak, J. Peruga, R. Krecki, J. Kasprzak, K. Ishii, T. Suyama, K. Kataoka, A. Furukawa, T. Nagai, M. Maenaka, Y. Seino, F. Musca, B. De Chiara, A. Moreo, S. Cataldo, M. Parolini, O. Parodi, T. Bombardini, F. Faita, S.-J. Park, J.-H. Kil, S.-J. Kim, S.-Y. Jang, S.-A. Chang, J.-O. Choi, S.-C. Lee, S. Park, P. Park, J. Oh, M. Cikes, V. Velagic, B. Biocina, H. Gasparovic, Z. Djuric, B. Bijnens, D. Milicic, A. Huqi, B. Klas, A. He, I. Paterson, M. Irween, J. Ezekovitz, J. Choy, Y. Chen, L. Cheng, R. Yao, H. Yao, H. Chen, C. Pan, X. Shu, B. Sobkowicz, M. Kaminska, W. Musial, R. Buechel, G. Sommer, G. Leibundgut, A. Rohner, J. Bremerich, B. Kaufmann, A. Kessel-Schaefer, M. Handke, A. Kiotsekoglou, S. Saha, R. Toole, S. Sharma, A. Gopal, S. Adhya, W. Tsang, C. Kenny, S. Kapetanakis, R. Lang, M. Monaghan, B. Smith, T. Coulter, A. Rendon, W.-S. Cheung, W. Gorissen, J. A. Ejlersen, O. May, F. J. Van Slochteren, T. Van Der Spoel, H. Hanssen, P. Doevendans, S. Chamuleau, C. De Korte, A. Tarr, S. Stoebe, T. Trache, J.-G. Kluge, A. Varga, A. Hagendorff, A. Nagy, A. Kovacs, A. Apor, B. Sax, D. Becker, B. Merkely, R. Lindquist, A. Miller, C. Reece, B. W. Eidem, W.-G. Choi, S. Kim, S. Oh, Y. Kim, R. Iacobelli, M. Chinali, M. D' Asaro, A. Toscano, A. Del Pasqua, C. Esposito, G. Seghetti, F. Parisi, G. Pongiglione, G. Rinelli, O. Omaygenc, R. Bakal, C. Dogan, K. Teber, S. Akpinar, G. Sahin, N. Ozdemir, A. Penhall, M. Joseph, F. Chong, C. De Pasquale, J. Selvanayagam, D. Leong, E. G. Nyktari, A. P. Patrianakos, C. Goudis, G. Solidakis, F. Parthenakis, P. Vardas, E. Nestaas, D. Fugelseth, A. Vitarelli, L. Capotosto, M. Bernardi, Y. Conde, F. Caranci, G. Placanica, O. Dettori, M. Vitarelli, S. De Chiara, V. De Cicco, M. Ferro', R. Calabro', S. Apostolakis, G. Chalikias, D. Tziakas, D. Stakos, A. Thomaidi, S. Konstantinides, G. Iorio, R. Rucos, G. Continanza, M. D Ascanio, L. Alessandroni, M. Saponara, M. Berry, J. Nahum, O. Zaghden, J. Monin, J. Couetil, O. Lairez, L. Macron, J. Dubois Rande, P. Gueret, P. Lim, M. Cameli, E. Giacomin, M. Lisi, S. Benincasa, F. Righini, D. Menci, M. Focardi, S. Mondillo, E. Philip, G. Gorincour, H. Bellsham-Revell, A. J. Bell, O. I. Miller, P. Beerbaum, R. Razavi, G. Greil, J. M. Simpson, S. Ann, T. Kim, J. Lee, J. Chin, P. Cabeza Lainez, V. Escolar Camas, L. Gheorghe, P. Fernandez Garcia, R. Vazquez Garcia, V. Caiulo, S. Caiulo, A. Fisicaro, F. Moramarco, G. Latini, A. Seale, J. Carvalho, H. Gardiner, M. Roughton, J. Simpson, A. Tometzki, O. Uzun, S. Webber, P. Daubeney, A. Dawood, G. Dwivedi, G. Mahadevan, D. Jiminez, R. Steeds, M. Frenneaux, C. H. Attenhofer Jost, B. Knechtle, A. Bernheim, M. Pfyffer, A. Linka, A. Faeh-Gunz, B. Seifert, G. De Pasquale, M. Zuber, A. Tomaszewski, A. Kutarski, and M. Tomaszewski
Subjects: Computer science, Plane (geometry), business.industry, Echo (computing), Left atrium, General Medicine, Biplane, medicine.anatomical_structure, Software, Left atrial, medicine, Radiology, Nuclear Medicine and imaging, Cardiology and Cardiovascular Medicine, business, Nuclear medicine
Published: 2011
Full Text: View/download PDF

58. Effects of hyperthyroidism, hypothyroidism, and thyroid autoimmunity on female sexual function

Author: F Atzeni, Alessandro Taberlet, Alessandro Oppo, Stefano Mariotti, and E Franceschi
Subjects: Adult, Male, Thyroid Hormones, endocrine system, medicine.medical_specialty, medicine.biofluid, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Sexual arousal, Thyroid Gland, Autoimmunity, Thyroid Function Tests, Hyperthyroidism, Thyroid function tests, Young Adult, Endocrinology, Hypothyroidism, Internal medicine, Humans, Medicine, Euthyroid, medicine.diagnostic_test, business.industry, Vaginal lubrication, Middle Aged, Prognosis, Sexual Dysfunction, Physiological, Sexual desire, Sexual dysfunction, Case-Control Studies, Female, medicine.symptom, Thyroid function, business, Sexual function, hormones, hormone substitutes, and hormone antagonists, Follow-Up Studies
Abstract: Introduction: Thyroid hormones affect male and female sexual functions, but data in hypo- and hyperthyroid women are scanty. Aim: To investigate sexual function in hypo- and hyperthyroid women before and immediately after restoration of euthyroidism and in women with euthyroid Hashimoto’s thyroiditis (HT). Patients and controls: Fifty-six women with thyroid diseases (age 19–50 yr; 22 with hyperthyroidism, 17 with hypothyroidism, and 17 with euthyroid HT) and 30 age-matched healthy women. Main outcome measures: Hypoactive sexual desire, disorders of sexual arousal, vaginal lubrication, orgasm, satisfaction, and sexual pain (SPD) were assessed by Female Sexual Function Index. Serum TSH, free T4 (FT4) and thyroid autoantibodies (anti-thyroglobulin, anti-thyroperoxidase, and TSH-receptor antibodies) were assessed at the diagnosis; FT4 and TSH were repeated after treatment to confirm normalization of thyroid function. Results: All sexual domains scores were significantly reduced (p ranging
Published: 2011
Full Text: View/download PDF

59. Vasculitis: 265. Cryoglobulinemic Vasculitis Secondary to Hepatitis C Infection: Is Prediction of Disease Severity Feasible?

Author: R. A. Ionescu, I. C. Daha, M. Sisiroi, C. Tanasescu, B. Dasgupta, C. Crowson, H. Maradit-Kremers, E. Matteson, T. Youngstein, P. Mehta, J. Mason, R. Suppiah, R. D. Hadden, R. Batra, N. Arden, M. P. Collins, L. Guillevin, D. Jayne, R. Luqmani, J. Mukherjee, D. Pyne, E. Hughes, J. Nash, J. Andrews, J. C. Mason, F. Atzeni, L. Boiardi, B. Casali, E. Farnetti, D. Nicoli, P. Sarzi-Puttini, N. Pipitone, I. Olivieri, F. Cantini, F. Salvi, R. La Corte, G. Triolo, D. Filippini, G. Paolazzi, C. Salvarani, J. Robson, O. Flossmann, L. Harper, P. Hoglund, A. Judge, C. Mukhtyar, K. Westman, M. Kassim Javaid, J. C. Davis, G. S. Hoffman, W. Joseph McCune, P. A. Merkel, E. William St. Clair, P. Seo, U. Specks, R. Spiera, and J. H. Stone
Subjects: business.industry, Hepatitis C virus, Hepatitis C, medicine.disease, medicine.disease_cause, Cerebral angiitis, Rheumatology, Disease severity, Antiphospholipid syndrome, Immunology, Severity of illness, Medicine, Pharmacology (medical), business, Vasculitis, Cryoglobulinemic vasculitis
Published: 2011
Full Text: View/download PDF

60. Poster session V * Saturday 11 December 2010, 08:30-12:30

Author: Q. H. Pham, T. G. Von Lueder, S. K. Namtvedt, H. Rosjo, T. Omland, K. Steine, A. T. Timoteo, M. Mota Carmo, M. Simoes, L. M. Branco, R. C. Ferreira, R. Kato, J. Ito, T. Tahara, Y. Yokoyama, T. Ashikaga, Y. Satoh, J. O. Na, H. E. Hong, M. N. Kim, S. Y. Shin, C. U. Choi, E. J. Kim, S. W. Rha, C. G. Park, H. S. Seo, D. J. Oh, R. Ticulescu, S. Brigido, O. Vriz, L. Sparacino, B. A. Popescu, C. Ginghina, S. Carerj, G. L. Nicolosi, F. Antonini-Canterin, J. J. Onaindia Gandarias, A. Romero, E. Laraudogoitia, S. Velasco, O. Quintana, A. Cacicedo, I. Rodriguez, J. A. Alarcon, J. Gonzalez, I. Lekuona, A. Subinas, G. Abdula, L. H. Lund, R. Winter, L. Brodin, A. Sahlen, M. Masaki, Y. M. Cha, T. Yuasa, K. Dong, Y. X. Dong, S. V. Mankad, J. K. Oh, F. Vallet, B. Lequeux, C. Diakov, P. Sosner, L. Christiaens, D. Coisne, C. Kihara, K. Murata, Y. Wada, K. Uchida, T. Ueyama, S. Okuda, T. Susa, M. Matsuzaki, E. J. Cho, K. Y. Choi, B. J. Kwon, D. B. Kim, S. W. Jang, J. S. Cho, H. O. Jung, H. K. Jeon, H. J. Youn, J. H. Kim, M. Cikes, B. Bijnens, V. Velagic, T. Kopjar, D. Milicic, B. Biocina, H. Gasparovic, I. Almuntaser, A. Brown, B. Foley, N. Mulvihill, P. Crean, G. King, R. Murphy, Y. Takata, M. Taniguchi, S. Nobusada, M. Sugawara, N. Toh, K. Kusano, H. Itoh, E. Wellnhofer, C. Kriatselis, S. Nedios, J. H. Gerds-Li, E. Fleck, M. K. Poulsen, J. E. Henriksen, J. Dahl, A. Johansen, T. Haghfelt, P. F. Hoilund-Carlsen, H. Beck-Nielsen, J. E. Moller, R. Dankowski, M. Wierzchowiecki, M. Michalski, A. Nowicka, K. Szymanowska, A. Pajak, K. Poprawski, A. Szyszka, M. Kasner, D. Westermann, H. P. Schultheiss, C. Tschoepe, T. Watanabe, M. Iwai-Takano, A. Kobayashi, H. Machii, Y. Takeishi, B. P. Paelinck, P. L. Van Herck, J. M. Bosmans, C. J. Vrints, H. J. Lamb, A. Doltra, B. Vidal, E. Silva, S. Poyatos, L. Mont, A. Berruezo, A. Castel, J. M. Tolosana, J. Brugada, M. Sitges, M. Dencker, O. Bjorgell, J. Hlebowicz, Z. S. Szelenyi, G. Szenasi, M. Kiss, Z. Prohaszka, A. Patocs, I. Karadi, A. Vereckei, S. K. Saha, P. L. Anderson, S. Govind, M. Govindan, J. C. Moggridge, A. Kiotsekoglou, A. S. Gopal, B. B. Loegstrup, T. B. Christophersen, D. E. Hoefsten, J. E. Moeller, H. E. Boetker, K. Egstrup, M. Graefe, F. Q. Huang, R. S. Zhang, T. T. Le, R. S. Tan, R. Sattarzadeh Badkoubeh, A. Tavoosi, A. R. Elahian, O. Drapkina, V. I. Ivashkin, A. Fazakas, L. Pepo, O. Janosi, I. Kopitovic, A. Goncalves, P. Marcos-Alberca, C. Almeria, G. Feltes, E. Rodriguez, E. Garcia, R. Hernandez-Antolin, C. Macaya, J. Silva Cardoso, J. L. Zamorano, M. S. Navarro, M. Valentin, C. M. Banes, F. Rigo, E. Grolla, F. Tona, V. Cuaia, A. Moreo, L. Badano, A. Raviele, S. Iliceto, P. Tarzia, A. Sestito, R. Nerla, A. Di Monaco, F. Infusino, D. Matera, F. Greco, R. M. Tacchino, G. A. Lanza, F. Crea, A. Nemes, E. Balazs, K. S. Pinter, A. Egyed, M. Csanady, T. Forster, E. Holte, J. Vegsundvag, T. Hole, K. Hegbom, R. Wiseth, D. Sharif, A. Sharif-Rasslan, C. Shahla, A. Khalil, U. Rosenschein, A. Zagatina, N. Zhuravskaya, T. V. Tyurina, E. Tagliamonte, T. Cirillo, A. Coppola, U. Marinelli, C. Romano, G. Riccio, R. Citro, C. Astarita, N. Capuano, G. Quaranta, A. Desiderio, S. Frattini, P. Faggiano, V. Zilioli, E. Locantore, S. Longhi, F. Bellandi, G. Faden, M. Triggiani, L. Dei Cas, M. Dalsgaard, J. Kjaergaard, K. Iversen, C. Hassager, W. Dinh, W. N. Nickl, J. S. Smettan, T. K. Koehler, T. D. Scheffold, M. C. B. Coll Barroso, J. G. Guelker, R. F. Fueth, V. Kamperidis, S. Hadjimiltiades, G. Sianos, G. Efthimiadis, H. Karvounis, G. Parcharidis, I. H. Styliadis, M. S. Velasco Del Castillo, J. J. Onaindia, M. Telleria, H. G. Carstensen, C. Nordenberg, P. Sogaard, T. Fritz-Hansen, J. Bech, S. Galatius, J. S. Jensen, R. Mogelvang, P. E. Bartko, S. Graf, R. Rosenhek, I. G. Burwash, J. Bergler-Klein, M.-A. Clavel, H. Baumgartner, P. Pibarot, G. Mundigler, B. Kirilmaz, I. Eser, N. Tuzun, B. Komur, H. Dogan, A. Taskiran Comez, E. Ercan, M. Cusma-Piccione, C. Zito, G. Oreto, S. Piluso, S. Tripepi, L. Oreto, C. Longordo, L. Ciraci, G. Di Bella, R. Piatkowski, J. Kochanowski, P. Scislo, M. Grabowski, M. Marchel, M. Roik, D. Kosior, G. Opolski, L. Sknouril, M. Dorda, B. Holek, L. Gajdusek, J. Chovancik, M. Branny, M. Fiala, P. Szymanski, M. Lipczynska, A. Klisiewicz, P. Hoffman, N. Jander, J. Minners, G. Martin, W. Zeh, M. Allgeier, C. Gohlke-Baewolf, H. Gohlke, S. Nistri, M. C. Porciani, M. Attanasio, R. Abbate, G. F. Gensini, G. Pepe, R. F. Duncan, C. Piantadosi, A. J. Nelson, G. Wittert, B. Dundon, M. I. Worthley, S. G. Worthley, P. Jung, K. Berlinger, J. Rieber, H. Z. Sohn, P. Schneider, M. Leibig, A. Koenig, V. Klauss, L. Tomkiewicz-Pajak, J. Kolcz, M. Olszowska, M. Pieculewicz, P. Podolec, T. Przewlocki, E. Suchon, B. Sobien, P. Wilkolek, A. Ziembicka, M. Hlawaty, A. Van De Bruaene, H. Hermans, R. Buys, L. Vanhees, M. Delcroix, J.-U. Voigt, W. Budts, E. De Cillis, T. Acquaviva, D. Basile, A. S. Bortone, D. Kalimanovska-Ostric, T. Nastasovic, B. Vujisic-Tesic, I. Jovanovic, B. Milakovic, M. Dostanic, M. Stosic, A. Frogoudaki, K. Andreou, J. Parisis, E. Triantafyllidi, S. Gaitani, J. Paraskevaidis, M. Anastasiou-Nana, G. De Pasquale, A. Kuehn, K. Petzuch, J. Mueller, C. Meierhofer, S. Fratz, A. Hager, J. Hess, M. Vogt, C. H. Attenhofer Jost, J. A. Dearani, C. G. Scott, H. M. Burkhart, H. M. Connolly, A. Vitarelli, D. Battaglia, F. Caranci, V. Padella, G. Continanza, O. Dettori, L. Capotosto, M. Vitarelli, V. De Cicco, M. Cortez Morichetti, K. K. Mohanan Nair, B. Sasidaharan, A. Thajudeen, J. M. Tharakan, L. Mertens, N. Ahmad, P. K. Kantor, L. Grosse-Wortmann, M. K. Friedberg, Y. F. Bernard, M. A. Morel, V. Descotes-Genon, J. Jehl, N. Meneveau, F. Schiele, M. Kaldararova, I. Simkova, P. Tittel, J. Masura, O. Trojnarska, L. Szczepaniak, K. Mizia -Stec, A. Cieplucha, A. Bartczak, S. Grajek, A. Tykarski, Z. Gasior, D. Babovicvuksanovic, C. R. Bonnichsen, G. J. Morgan, C. Slorach, W. Hui, T. Sarkola, K. J. Lee, R. Chaturvedi, L. Benson, T. Bradley, M. E. Iancu, I. Ghiorghiu, M. Serban, I. Craciunescu, A. Hodo, J. Morgan, L. Roche, K. Lee, O. Milanesi, V. Favero, M. Padalino, R. Biffanti, A. Cerutti, N. Maschietto, E. Reffo, V. Vida, G. Stellin, O. Irtyuga, D. Gamazin, I. Voronkina, N. Tsoyi, E. Gudkova, O. Moiseeva, C. Aggeli, C. Kazazaki, I. Felekos, S. Lagoudakou, G. Roussakis, J. Skoumas, C. Pitsavos, C. Stefanadis, C. Cueff, N. Keenan, P. G. Steg, C. Cimadevilla, G. Ducrocq, A. Vahanian, D. Messika-Zeitoun, L. Petrella, A. M. Mazzola, C. V. Villani, R. G. Giancola, M. C. Ciocca, D. E. M. Di Eusanio, S. Nolan, A. Ionescu, T. R. Skaug, B. H. Amundsen, T. Hergum, H. Torp, B. O. Haugen, J. Lopez Aguilera, D. Mesa Rubio, M. Ruiz Ortiz, M. Delgado Ortega, E. Villanueva Fernandez, L. Cejudo Diaz Del Campo, F. Toledano Delgado, M. Leon Del Pino, E. Romo Pena, J. Suarez De Lezo Cruz-Conde, E. De Marco, A. Colucci, G. Comerci, F. A. Gabrielli, R. Natali, B. Garramone, M. Savino, M. Lotrionte, A. Sonaglioni, F. Loperfido, M. Zdravkovic, J. Perunicic, M. Krotin, M. Ristic, V. Vukomanovic, M. Zaja, S. Radovanovic, J. Saric, D. Zdravkovic, C. Cotrim, A. R. Almeida, R. Miranda, A. G. Almeida, E. Picano, M. Carrageta, A. D'andrea, R. Cocchia, L. Riegler, E. Golia, R. Scarafile, P. Caso, M. G. Russo, E. Bossone, R. Calabro', H. Noman, A. Adel, A. M. R. Elfaramawy, M. Abdelraouf, W. A. E. L. Elnaggar, E. Baligh, L. Sargento, D. Silva, S. Goncalves, S. Ribeiro, G. Vinhas Sousa, A. Almeida, M. Lopes, M. Rodriguez-Manero, L. Aguado Gil, P. Azcarate, P. Lloret Luna, A. Macias Gallego, S. A. R. A. Castano, M. Garcia, C. Pujol Salvador, J. Barba, P. Redondo, L. Tomasoni, S. Sitia, F. Atzeni, L. Gianturco, C. Ricci, P. Sarzi-Puttini, M. Turiel, V. De Gennaro Colonna, T. Uejima, J. Jaroch, C. Polombo, A. Hughes, D. Vinereanu, A. Evanvelista, G. Leftheriotis, A. G. Fraser, A. Lewczuk, B. Sobkowicz, A. Tomaszuk-Kazberuk, R. Sawicki, T. Hirnle, B. W. Michalski, D. Filipiak, J. D. Kasprzak, P. Lipiec, H. Dalen, O. C. Mjolstad, B. E. Klykken, T. Graven, M. Martensson, M. Olsson, L.-A. Brodin, R. Enache, E. Leiballi, A. Penhall, R. Perry, M. Altman, A. Sinhal, J. Bennetts, D. P. Chew, M. X. Joseph, L. H. Larsen, T. Kristensen, L. V. Kober, K. F. Kofoed, F. Moscoso Costa, R. Ribeiras, J. Brito, S. Boshoff, J. Neves, R. Teles, M. Canada, M. J. Andrade, R. Gouveia, A. Silva, A. Miskovic, T. P. Poerner, C. S. Stiller, B. G. Goebel, A. M. Moritz, L. Stefani, G. G. Galanti, M. Moraldo, C. Bergamini, P. A. Pabari, N. M. Dhutia, A. S. N. Malaweera, K. Willson, J. Davies, A. D. Hughes, X. Y. Xu, D. P. Francis, R. Jasaityte, B. Amundsen, D. Barbosa, D. Loeckx, G. Kiss, F. Orderud, V. Robesyn, P. Claus, J. D'hooge, T. Nao, T. Miura, K. Shams, S. Samir, R. Samir, M. El-Sayed, A. M. Anwar, Y. Nosir, A. Galal, H. Chamsi-Pasha, A. Ciobanu, R. Dulgheru, S. Bennett, A. De Luca, L. Toncelli, F. Cappelli, B. Cappelli, M. C. R. Vono, G. Galanti, Y. Zorman, M. S. Yilmazer, M. Akyildiz, T. Gurol, A. Aydin, B. Dagdeviren, and A. Kalangos
Subjects: medicine.medical_specialty, business.industry, Physical therapy, Medicine, Radiology, Nuclear Medicine and imaging, General Medicine, Session (computer science), Cardiology and Cardiovascular Medicine, business
Published: 2010
Full Text: View/download PDF

61. Poster session II * Thursday 9 December 2010, 14:00-18:00

Author: P. A. Pabari, A. Kyriacou, M. Moraldo, B. Unsworth, R. Baruah, N. Sutaria, A. Hughes, J. Mayet, D. P. Francis, T. Uejima, K. Loboz, F. Antonini-Canterin, C. Polombo, S. Carerj, D. Vinereanu, A. Evangelista, G. Leftheriotis, A. G. Fraser, A. Kiotsekoglou, M. Govindan, S. C. Govind, S. K. Saha, A. J. Camm, P. M. Azcarate, S. Castano, M. Rodriguez-Manero, M. Arraiza, B. Levy, J. Barba, G. Rabago, G. Bastarrika, A. Nemes, R. Takacs, T. Varkonyi, H. Gavaller, I. Baczko, T. Forster, T. Wittmann, J. G. Papp, C. Lengyel, A. Varro, L. R. Tumasyan, K. G. Adamyan, O. Savu, T. Mieghem, P. Dekoninck, L. Gucciardo, R. Jurcut, S. Giusca, B. A. Popescu, C. Ginghina, J. Deprest, J. U. Voigt, M. Versiero, M. Galderisi, R. Esposito, A. Rapacciuolo, G. Esposito, R. Raia, T. Morgillo, F. Piscione, G. De Simone, M. A. Oraby, F. A. Maklady, E. M. Mohamed, A. Z. Eraki, D. Zaliaduonyte-Peksiene, E. Tamuleviciute, J. Janenaite, J. Marcinkeviciene, V. Mizariene, S. Bucyte, J. Vaskelyte, D. Trifunovic, I. Nedeljkovic, D. Popovic, M. Ostojic, B. Vujisic-Tesic, M. Petrovic, S. Stankovic, D. Sobic-Saranovic, M. Banovic, A. Dikic-Djordjevic, K. Savino, A. Lilli, E. Grikstaite, V. Giglio, E. Bordoni, G. Maragoni, C. Cavallini, G. Ambrosio, B. Jakovljevic, B. Beleslin, M. Nedeljkovic, O. Petrovic, S. Moral, J. Rodriguez-Palomares, M. Descalzo, G. Marti, V. Pineda, P. Mahia, L. Gutierrez, T. Gonzalez-Alujas, D. Garcia-Dorado, F. Schnell, E. Donal, C. Thebault, A. Bernard, H. Corbineau, H. Le Breton, J. Kochanowski, P. Scislo, R. Piatkowski, M. Roik, M. Marchel, D. Kosior, G. Opolski, A. M. Lesniak-Sobelga, E. Wicher-Muniak, M. Kostkiewicz, M. Olszowska, E. Suchon, P. Klimeczek, P. Banys, M. Pasowicz, W. Tracz, P. Podolec, A. Laynez, D. E. Hoefsten, B. B. Loegstrup, B. Norager, J. E. Moller, A. Flyvbjerg, K. Egstrup, W. Streb, M. Szulik, J. Nowak, E. Markowicz-Pawlus, A. Duszanska, A. Sedkowska, Z. Kalarus, T. Kukulski, L. Spinelli, C. Morisco, E. Assante Di Panzillo, F. Buono, S. Crispo, B. Trimarco, A. A. Hawary, G. M. Nasr, M. M. Fawzy, L. Faber, W. Scholtz, J. Boergermann, M. Wiemer, G. Kleikamp, N. Bogunovic, Z. Dimitriadis, J. Gummert, D. Hering, D. Horstkotte, F. Luca', S. Gelsomino, R. Lorusso, S. Caciolli, R. Carella, G. Bille', G. De Cicco, V. Pazzagli, G. F. Gensini, A. Borowiec, R. Dabrowski, J. Janas, A. Kraska, B. Firek, I. Kowalik, H. Szwed, K. A. Marcus, C. L. De Korte, T. Feuth, J. M. Thijssen, L. Kapusta, J. Dahl, L. Videbaek, M. K. Poulsen, P. A. Pellikka, K. Veien, L. I. Andersen, T. Haghfelt, M. Haberka, K. Mizia - Stec, T. Adamczyk, M. Mizia, A. Chmiel, P. Pysz, M. Sosnowski, Z. Gasior, M. Trusz - Gluza, M. Tendera, T. Niklewski, K. Wilczek, P. Chodor, T. Podolecki, A. Frycz-Kurek, M. Zembala, S. Yurdakul, O. Yildirimturk, Y. Tayyareci, K. Memic, I. C. C. Demiroglu, S. Aytekin, C. J. Garcia Alonso, E. Ferrer Sistach, L. Delgado, J. Lopez Ayerbe, N. Vallejo Camazon, F. Gual Capllonch, M. Espriu Simon, X. Ruyra, A. Caballero Parrilla, A. Bayes Genis, L. Lecuyer, A. Berrebi, E. Florens, M. Noghin, C. Huerre, P. Achouh, R. Zegdi, J. N. Fabiani, B. De Chiara, A. Moreo, F. Musca, F. De Marco, E. Lobiati, O. Belli, F. Mauri, S. Klugmann, A. Caballero, N. Vallejo, A. Gonzalez Guardia, R. Nunez Aragon, C. Bosch, E. Ferrer, M. L. Pedro Botet, F. Gual, M. Cusma-Piccione, C. Zito, G. Oreto, R. Giuffre, M. C. Todaro, C. M. Barbaro, S. Lanteri, C. Longordo, J. Salvia, A. Bensaid, R. Gallet, E. Fougeres, P. Lim, J. Nahum, J. F. Deux, P. Gueret, E. Teiger, J. L. Dubois-Rande, J. L. Monin, F. Behramoglu, Z. Colakoglu, V. Aytekin, C. Demiroglu, L. Gargani, E. Poggianti, R. Bucalo, M. Rizzo, F. Agrusta, P. Landi, R. Sicari, E. Picano, A. Sutandar, B. B. Siswanto, I. Irmalita, G. Harimurti, S. Y. Hayashi, M. M. Nascimento, B. Lindholm, B. Lind, A. Seeberger, M. A. Pachaly, M. C. Riella, A. Bjallmark, L. A. Brodin, L. Poanta, M. Porojan, D. L. Dumitrascu, I. Ikonomidis, S. Tzortzis, J. Lekakis, D. T. Kremastinos, I. Paraskevaidis, I. Andreadou, M. Nikolaou, P. Katsibri, M. Anastasiou-Nana, A. M. Maceira Gonzalez, C. Ripoll, J. Cosin-Sales, B. Igual, J. Salazar, V. Belloch, J. Cosin-Aguilar, D. J. Pennell, M. Masaki, J. N. Pulido, T. Yuasa, S. Gillespie, B. Afessa, D. R. Brown, S. V. Mankad, J. K. Oh, A. L. Gurghean, A. M. Mihailescu, I. Tudor, C. Homentcovschi, M. Muraru, I. V. Bruckner, C. E. Correia, B. Rodrigues, D. Moreira, L. F. Santos, P. Gama, O. Dionisio, C. Cabral, O. Santos, T. Bombardini, S. Gherardi, G. Arpesella, S. Valente, I. Calamai, E. Pasanisi, S. Sansoni, P. Szymanski, P. Dobrowolski, M. Lipczynska, A. Klisiewicz, P. Hoffman, D. Stepowski, B. Kurtz, G. Grezis-Soulie, A. Savoure, F. Anselme, F. Bauer, J. Castillo, N. Herszkowicz, C. Ferreira, A. Goscinska, K. Mizia-Stec, W. Poborski, O. Azevedo, I. Quelhas, J. Guardado, M. Fernandes, C. S. Miranda, P. Gaspar, A. Lourenco, R. Medeiros, J. Almeida, S. L Bennani, V. Algalarrondo, S. Dinanian, J. Guiader, C. Juin, D. Adams, M. S. Slama, J. J. Onaindia, O. Quintana, S. Velasco, E. Astigarraga, A. Cacicedo, J. Gonzalez, I. Rodriguez, M. Sadaba, M. Eneriz, E. Laraudogoitia Zaldumbide, I. Nunez-Gil, M. Luaces, J. Zamorano, J. C. Garcia Rubira, D. Vivas, B. Ibanez, P. Marcos Alberca, C. Fernandez Golfin, J. Alonso, C. Macaya, J. Silva Marques, A. G. Almeida, V. Carvalho, C. Jorge, D. Silva, M. Gato Varela, S. Martins, D. Brito, M. G. Lopes, E. Tripodi, B. Miserrafiti, V. Montemurro, R. Scali, P. Tripodi, A. Winkler, A. Madej, I. Hausmanowa-Petrusewicz, M. Fijalkowski, A. Koprowski, M. Jaguszewski, R. Galaska, M. Taszner, A. Rynkiewicz, R. Citro, F. Rigo, G. Provenza, Q. Ciampi, M. M. Patella, A. D'andrea, O. Vriz, C. Astarita, E. Bossone, F. Heggemann, T. H. Walter, T. H. Kaelsch, T. Sueselbeck, T. H. Papavassiliu, M. Borggrefe, D. Haghi, T. Monk-Hansen, C. Have Dall, S. Bisgaard Christensen, M. Snoer, F. Gustafsson, H. Rasmusen, E. Prescott, G. Finocchiaro, B. Pinamonti, M. Merlo, G. Barbati, A. Di Lenarda, R. Bussani, G. Sinagra, T. Butz, C. N. Lang, A. Meissner, G. Plehn, H. Yeni, C. Langer, H. J. Trappe, X. Gu, X. Y. Gu, Y. H. He, Z. A. Li, J. C. Han, J. Chen, P. Gaudron, M. Niemann, S. Herrmann, K. Hu, B. Bijnens, H. Hillenbrand, M. Beer, G. Ertl, F. Weidemann, A. Mazzone, M. Mariani, I. Foffa, A. Vianello, S. Del Ry, S. Bevilacqua, M. G. Andreassi, M. Glauber, S. Berti, M. Grabowski, M. Postula, A. Dragulescu, G. Van Arsdell, O. Al-Radi, C. Caldarone, L. Mertens, K. J. Lee, R. P. Casula, H. Yadav, A. Cherian, A. D. Hughes, A. Vitarelli, S. D'orazio, B. L. Nguyen, G. Iorio, D. Battaglia, F. Caranci, V. Padella, L. Capotosto, L. Alessandroni, F. Barilla, C. Cardin, S. Hascoet, M. Saudron, G. Caudron, B. Arnaudis, P. Acar, M. M. Sun, X. H. Shu, C. Z. Pan, X. Y. Fang, D. H. Kong, F. Fang, Q. Zhang, Y. S. Chan, J. M. Xie, W. K. Yip, Y. Y. Lam, J. E. Sanderson, C. M. Yu, M. Rosca, K. O' Connor, G. Romano, J. Magne, A. Calin, D. Muraru, L. Pierard, P. Lancellotti, A. Roushdy, I. Elfiky, G. El Shahid, A. Elfiky, M. El Sayed, K. Wierzbowska-Drabik, L. Chrzanowski, A. Kapusta, E. Plonska-Goscinak, M. Krzeminska-Pakula, M. Kurpesa, T. Rechcinski, E. Trzos, J. D. Kasprzak, M. K. Ersboll, N. Valeur, U. M. Mogensen, M. Andersen, C. Hassager, P. Sogaard, L. V. Kober, M. Kloeckner, D. Hayat, C. Dussault, N. Lellouche, N. Elbaz, A. Demopoulos, G. Hatzigeorgiou, E. Leontiades, A. Motsi, G. Karatasakis, G. Athanassopoulos, P. Zycinski, J. Kasprzak, M. C. Vazquez Alvarez, C. Medrano Lopez, M. Camino Lopez, S. Granja, J. L. Zunzunegui Martinez, E. Maroto Alvaro, W.-C. Tsai, J.-Y. Chen, Y.-W. Liu, C.-C. Lin, L.-M. Tsai, D. C. Gomes, S. Robalo Martins, M. R. Gois, S. Ribeiro, A. Nunes Diogo, P. Sengupta, G. Di Bella, G. Caracciolo, S. Lentini, E. Kinova, N. Zlatareva, A. Goudev, N. Papagiannis, M. Mpouki, A. Papagianni, M. Vorria, G. Mpenetos, D. Lytra, E. Papadopoulou, P. Sgourakis, J. Malakos, J. Kyriazis, V. Kodali, R. Toole, A. S. Gopal, J. Celutkiene, A. Rudys, V. Grabauskiene, S. Glaveckaite, E. Sadauskiene, Z. Lileikiene, N. Bickauskaite, E. Ciburiene, V. Skorniakov, A. Laucevicius, C. H. Attenhofer Jost, M. Pfyffer, R. Lindquist, J. L. F. Santos, O. R. C. Coelho, C. M. Mady, M. H. P. Picard, V. M. C. Salemi, L. Funk, M. W. Prull, J.-Y. Shih, Y.-Y. Huang, K. O'connor, M. Moonen, L. A. Pierard, D. C. Cozma, C. Mornos, A. Ionac, L. Petrescu, D. Dragulescu, R. Dan, I. Popescu, S. I. Dragulescu, T. G. Von Lueder, A. Hodt, G. F. Gjerdalen, T. E. Andersen, E. E. Solberg, K. Steine, T. Van Mieghem, M. Rostek, W. Pikto-Pietkiewicz, M. Dluzniewski, A. Antoniewicz, S. Poletajew, A. Borowka, T. Pasierski, S. K. Malyutina, M. Ryabikov, J. Ragino, A. Ryabikov, S. Sitia, L. Tomasoni, F. Atzeni, L. Gianturco, P. Sarzi-Puttini, V. De Gennaro Colonna, M. Turiel, F. R. Gutierrez, G. Lefhtheriotis, R. T. Hurst, M. R. Nelson, F. Mookadam, V. Thota, U. Emani, M. Al Harthi, J. Stepanek, S. Cha, S. J. Lester, E. M. M. Ho, L. Hemeryck, M. Hall, K. Scott, K. Bennett, A. Mahmud, C. Daly, G. King, R. T. Murphy, A. S. Brown, A. J. Teske, J. D'Hooge, P. Claus, F. Rademakers, L. Santos, N. Cortez-Dias, S. Goncalves, M. Almeida Ribeiro, A. Bordalo E Sa, C. Magnino, P. Marcos-Alberca, A. Milan, C. Almeria, V. Caniadas, J. L. Rodrigo, L. Perez De Isla, J. L. Zamorano, U. Gustafsson, M. Larsson, P. Lindqvist, L. Brodin, A. Waldenstrom, B. Roosens, S. Hernot, S. Droogmans, G. Van Camp, T. Lahoutte, B. Cosyns, C. M. Rao, D. Aguglia, G. Casciola, C. Imbesi, A. Marvelli, M. Sgro, D. Benedetto, R. Tripepi, C. Zoccali, F. A. Benedetto, L. P. Badano, M. Cardillo, L. Del Mestre, P. Gianfagna, A. Proclemer, H. D. Tschernich, B. Mora, E. Base, U. Weber, J. Dumfarth, C. Mukherjee, H. S. Skaltsiotis, A. K. Kaladaridis, D. B. Bramos, G. K. Kottis, A. A. Antoniou, I. A. Agrios, D. T. Takos, N. V. Vasiladiotis, K. P. Pamboucas, S. T. T. Toumanidis, A. Shim, P. Lipec, B. Michalski, B. Wozniakowski, L. Stefanczyk, A. Rotkiewicz, M. Cameli, M. Lisi, M. Padeletti, E. Bigio, S. Bernazzali, C. Tsoulpas, M. Maccherini, M. Henein, S. Mondillo, I. Garcia Lunar, S. Mingo Santos, V. Monivas Palomero, C. Mitroi, P. Beltran Correas, L. Ruiz Bautista, A. Muniz Lozano, M. Gonzalez Gonzalez, B. Stegemann, K. Willson, R. Zeppellini, A. Iavernaro, M. Zadro, M. Carasi, R. De Domenico, T. Rigo, E. Artuso, G. Erente, A. Ramondo, T. T. Le, F. Q. Huang, Y. Gu, and R. S. Tan
Subjects: Cardiac function curve, medicine.medical_specialty, medicine.anatomical_structure, business.industry, Ventricle, Internal medicine, medicine, Cardiology, Radiology, Nuclear Medicine and imaging, General Medicine, Cardiology and Cardiovascular Medicine, Rotation, business
Published: 2010
Full Text: View/download PDF

62. Subclinical impairment of myocardial and endothelial functionality in very early psoriatic and rheumatoid arthritis patients: Association with vitamin D, inflammation and activity

Author: F. Savarino, A. Lo Gullo, J.R. Carrìo, C.O. Aragona, A. Suárez, F. Atzeni, A. Saitta, and G. Mandraffino
Subjects: Cardiology and Cardiovascular Medicine
Published: 2018
Full Text: View/download PDF

63. Calcitonin Measurement in Wash-Out Fluid from Fine Needle Aspiration of Neck Masses in Patients with Primary and Metastatic Medullary Thyroid Carcinoma

Author: Giovanni Pinna, F Atzeni, Ivan Maurelli, Stefano Mariotti, Mario Piga, Maria Letizia Lai, and Francesco Boi
Subjects: Adult, Calcitonin, Male, Thyroid nodules, medicine.medical_specialty, endocrine system diseases, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Biopsy, Fine-Needle, Clinical Biochemistry, Neck mass, Biochemistry, Thyroid carcinoma, Endocrinology, Internal medicine, Biopsy, Biomarkers, Tumor, medicine, Humans, Thyroid Neoplasms, Thyroid Nodule, Thyroid cancer, Aged, medicine.diagnostic_test, business.industry, Biochemistry (medical), Thyroidectomy, Middle Aged, respiratory system, medicine.disease, Body Fluids, Fine-needle aspiration, Medullary carcinoma, Lymphatic Metastasis, Female, Neoplasm Recurrence, Local, medicine.symptom, business, Follow-Up Studies
Abstract: The aim of the study was to evaluate the usefulness of calcitonin (CT) assay in fine-needle aspiration biopsy (FNAB) wash-out fluid alone or combined with cytology in the presurgical study of medullary thyroid carcinoma (MTC) patients with thyroid nodules (TNs) and of suspicious neck MTC recurrences/metastases.A total of 36 ultrasound-guided FNABs were performed in neck masses from 23 patients with borderline or high basal and pentagastrin-stimulated serum CT. Cytology and CT-FNAB were performed on a total of 18 TNs and three neck lymph nodes (LNs) from 12 patients examined before thyroidectomy, and on six suspicious local recurrences (LRs) and nine LNs from nine totally thyroidectomized MTC patients. On the basis of CT-FNAB values found in 15 non-MTC lesions, CT-FNAB more than 36 pg/ml was considered as indicative of MTC.All 21 positive CT-FNAB lesions (10 TNs, six LNs, and five LRs), 13 with positive cytology, were confirmed as MTC at histology. Of the 15 negative CT-FNAB suspicious masses (eight TNs, six LNs, and one LR), five displayed a benign lesion at histology. The remaining 10 cases, all with benign cytology, were not operated on, and no evidence of MTC was detected at follow-up. CT-FNAB reached 100% sensitivity and specificity for MTC, while cytology displayed 61.9% sensitivity and 80% specificity.Ultrasound-guided CT-FNAB was the best tool to identify primary MTC and LRs/node metastases in MTC operated subjects. This may have important implications in the management of MTC.
Published: 2007
Full Text: View/download PDF

64. Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency

Author: Graziano Onder, Alessandra Marengoni, Pierluigi Russo, Luca Degli Esposti, Massimo Fini, Alessandro Monaco, Stefano Bonassi, Katie Palmer, Walter Marrocco, Giuseppe Pozzi, Diego Sangiorgi, Stefano Buda, Niccolò Marchionni, Federica Mammarella, Roberto Bernabei, Luca Pani, Sergio Pecorelli, S. Martinetti, P. Mero, L. Raeli, S. Migliazza, M. Dellagiovanna, C. Cerra, M. Gambera, R. Piccinelli, M. Zambetti, F. Atzeni, V. Valsecchi, P. DeLuca, E. Scopinaro, D. Moltoni, E. Pini, O. Leoni, C. Oria, M. Papagni, G. Nosetti, E. Caldiroli, V. Moser, R. Roni, A. Polverino, C. Bovo, L. Mezzalira, M. Andretta, L. Trentin, S. Palcic, A. Pettinelli, A. Arbo, A. Bertola, G. Capparoni, C. Cattaruzzi, L. Marcuzzo, F.V. Rosa, B. Basso, M. Saglietto, S. Delucis, M. Prioli, R. Filippi, A. Coccini, M. Ghia, F. Sanfelici, S. Radici, P. Scanavacca, A. Campi, S. Bianchi, A. Verzola, M. Morini, M. Borsari, A. Danielli, M. Dal Maso, B. Marsiglia, B. Vujovic, M. Pisani, P. Bonini, F. Lena, P. Aletti, A. Marcobelli, S. Sagratella, S. Fratini, F. Bartolini, G. Riccioni, A. Meneghini, R. Di Turi, V. Fano, A. Blasi, E. Pagnozzi, G. Quintavalle, P. D'Avenia, M.C. De Matthaeis, F. Ferrante, S. Crescenzi, L. Marziale, P. Venditti, C. Bianchi, I. Senesi, R. Baci, I. De Carlo, A. Lavalle, G. Trofa, G. Marcello, C. Pagliaro, C. Troncone, G. Farina, M.G. Tari, G. Motola, F. De Luca, M.L. Saltarelli, C. Granieri, M. Vulnera, L. Palumbo, F. La Viola, L. Florio, A.E. De Francesco, D. Costantino, F. Rapisarda, P.L. Lazzaro, M. Pastorello, M. Parelli, M. Visconti, I. Uomo, P. Sanna, and F. Lombardo
Subjects: end of life, Male, medicine.medical_specialty, Pediatrics, Databases, Factual, Alternative medicine, 030204 cardiovascular system & hematology, Medication prescription, Drug Prescriptions, Databases, 03 medical and health sciences, 0302 clinical medicine, Age Distribution, Age groups, Agency (sociology), 80 and over, Medicine, Humans, 030212 general & internal medicine, Medical prescription, Prescribed medications, Nursing (all)2901 Nursing (miscellaneous), Factual, General Nursing, Aged, Polypharmacy, Aged, 80 and over, Terminal Care, business.industry, Medicine (all), Health Policy, Settore MED/09 - MEDICINA INTERNA, End of life, Prescribing, Cross-Sectional Studies, Female, Italy, General Medicine, Oldest old, Geriatrics and Gerontology, business, polypharmacy
Abstract: In older adults co-occurrence of multiple diseases often leads to use of multiple medications (polypharmacy). The aim of the present study is to describe how prescription of medications varies across age groups, with specific focus on the oldest old.We performed a cross-sectional study using 2013 data from the OsMed Health-DB database (mean number of medicines and defined daily doses prescribed in 15,931,642 individuals). There were 3,378,725 individuals age 65 years or older (21.2% of the study sample).The mean number of prescribed medications progressively rose from 1.9 in the age group65 years to 7.4 in the age group 80-84 years and then declined, with a more marked reduction in the age group 95 years or older with a mean number of 2.8 medications. A similar pattern was observed for the mean number of defined daily doses. Among participants age ≥65 years, proton pump inhibitors were the most commonly prescribed medication (40.9% of individuals ≥65 years), followed by platelet aggregation inhibitors (32.8%) and hydroxy-methylglutaryl-coenzyme A reductase inhibitors (26.1%). A decline in prescription was observed among individuals age 90 years or older, but this reduction was less consistent for medications used to treat acute conditions (ie, antibiotics and glucocorticoids) rather than preventive medicines commonly used to treat chronic diseases (ie, antihypertensive medications and hydroxy-methylglutaryl-coenzyme A reductase inhibitors).The burden of medication treatment progressively increases till age 85 and substantially declines after age of 90 years. Patterns of medication prescription widely vary across age groups.
Published: 2015

65. The Diagnostic Value for Differentiated Thyroid Carcinoma Metastases of Thyroglobulin (Tg) Measurement in Washout Fluid from Fine-Needle Aspiration Biopsy of Neck Lymph Nodes Is Maintained in the Presence of Circulating Anti-Tg Antibodies

Author: Ml Lai, Gavino Faa, Francesco Boi, G. Baghino, F. Atzeni, and Stefano Mariotti
Subjects: Adult, Male, Thyroid nodules, medicine.medical_specialty, Pathology, Adolescent, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Clinical Biochemistry, Thyroid Function Tests, Thyroglobulin, Biochemistry, Thyroid carcinoma, Endocrinology, Internal medicine, Biomarkers, Tumor, Humans, Medicine, Thyroid Neoplasms, Child, Thyroid cancer, Aged, medicine.diagnostic_test, business.industry, Biopsy, Needle, Biochemistry (medical), Thyroid, Thyroidectomy, Middle Aged, medicine.disease, Fine-needle aspiration, medicine.anatomical_structure, Cervical lymph nodes, Lymphatic Metastasis, Female, Lymph Nodes, business, Neck, Immunoglobulins, Thyroid-Stimulating
Abstract: Serum thyroglobulin (Tg) is the marker of differentiated thyroid carcinoma (DTC) after total thyroidectomy, but its value is limited by the interference of anti-Tg antibodies (TgAb). Detection of Tg in fine-needle aspiration biopsy (Tg-FNAB) washout fluid is used to identify neck DTC recurrences/metastases, but the interference of serum TgAb in this procedure is unknown.Seventy-three patients (41 after surgery for thyroid cancer and 32 with thyroid nodules) evaluated for suspicious cervical lymph nodes were retrospectively reviewed. Tg was assayed by immunoradiometric assay or chemiluminescent assay in ultrasound-guided FNAB used for cytology. Serum TgAb were detected by passive agglutination or chemiluminescent assay. On the basis of preliminary data obtained in lymphadenitis, Tg-FNAB more than 36 ng/ml and more than 1.7 ng/ml (in the presence or absence of thyroid gland, respectively) was considered as indicative of metastasis.In 51 TgAb-negative patients, Tg-FNAB was positive in 15 (12 with malignant and three with nondiagnostic cytology), all with histologically confirmed DTC metastases. Of the remaining 36 patients with negative Tg-FNAB, 30 had nonsuspicious and six had suspicious cytology. Histology of the latter showed four undifferentiated thyroid cancer metastases and two lymphadenitis. In 22 TgAb-positive patients, Tg-FNAB was positive in 14 (12 with malignant and two with nondiagnostic cytology), all with histologically confirmed DTC metastases.Clinical performance of Tg-FNAB appears to be not substantially affected by TgAb, and this procedure remains superior to cytology in the identification of DTC neck metastases. However, cytology should always be performed because, irrespective of TgAb, Tg is undetectable in FNAB from undifferentiated metastases.
Published: 2006
Full Text: View/download PDF

66. Cardiac imaging techniques in systemic autoimmune diseases

Author: F. Atzeni, Maurizio Turiel, Andrea Doria, Piercarlo Sarzi-Puttini, and Rossana Peretti
Subjects: Diagnostic Imaging, medicine.medical_specialty, Heart Diseases, medicine.medical_treatment, 030204 cardiovascular system & hematology, Coronary Angiography, Autoimmune Diseases, Coronary artery disease, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Internal medicine, medicine, Humans, Stroke, Cardiac catheterization, 030203 arthritis & rheumatology, medicine.diagnostic_test, business.industry, Coronary flow reserve, Heart, medicine.disease, Coronary Vessels, Coronary arteries, medicine.anatomical_structure, Echocardiography, Angiography, Cardiology, Cardiac Imaging Techniques, Radiology, business, Echocardiography, Transesophageal, Artery
Abstract: Systemic autoimmune disorders are frequently associated to cardiac involvement and to a high prevalence of ischemic coronary events, often occurring at ayounger age than in the normal population. Large increase in mortality is related to premature atherosclerosis with coronary artery disease and stroke in patients with connective tissue diseases. Coronary heart disease is responsible for 40-50% of the deaths of patients with rheumatoid arthritis. Transesophageal or transthoracic echocardiography are the most useful and noninvasive techniques able to detect not only valvular abnormalities, embolic sources or pulmonary hypertension, but also left ventricular systolic or diastolic dysfunction. Furthermore, the introduction of new indexes, contrast agents and software increased the accuracy of this technique. It is possible now to evaluate coronary flow reserve by transthoracic echocardiography in patients with systemic autoimmune disease in order to detect microvasculature disorder. However, an ischemic response in a symptomatic patient requires, in most cases, further evaluation with cardiac catheterization. Coronary artery imaging allows confirmation of the presence, extent and position of atheromatous lesions. More recently, other imaging modalities including magnetic resonance and computerized tomography angiography have been developed to allow imaging of the coronary arteries.
Published: 2005
Full Text: View/download PDF

67. Fibromyalgia: a never-ending story of central and peripheral pain mechanisms

Author: P, Sarzi-Puttini and F, Atzeni
Subjects: Fibromyalgia, Humans, Pain, Sensory Gating
Published: 2014

68. Strategies for Early Identification of Atherosclerosis in Systemic Autoimmune Disease

Author: Colombo C, P. Sarzi-Puttini, S. Galaverna, Bruno Dino Bodini, F. Atzeni, Turiel M, D. Stella, and Gianturco L
Subjects: medicine.medical_specialty, business.industry, Inflammation, Disease, Omics, Disease cluster, medicine.disease_cause, Autoimmunity, Disease susceptibility, Autoimmune vasculitis, Internal medicine, Immunology, medicine, medicine.symptom, business
Abstract: Systemic autoimmune diseases (SADs) are associated with significantly enhanced cardiovascular (CV) morbidity and mortality due to a cluster of risk factors. Among them we find traditional markers of CV risk but also specific risk factors principally related to inflammation and autoimmunity. Therefore, CV involvement assessment in those diseases is more and more important and several authors have been studying for the last years that phenomenon. The most important goal for all of them is CV prevention and follow-up of subjects with such abnormalities; in particular, CV burden is mainly due to atherosclerosis (ATS). So, in order to achieve the best CV prevention program a very early diagnose of ATS in these patients (pts) is fundamental, especially in those phases of disease in which no symptoms are present and clinical manifestations are not clearly visible. In this review, our aim was to find the best marker for identifying early ATS in systemic autoimmune diseases (SADs) by starting our long experience in this field.
Published: 2014
Full Text: View/download PDF

69. The Sardinian Autoimmunity Study. 4. Thyroid and islet cell autoantibodies in Sardinian pregnant women at delivery: A cross-sectional study

Author: S. Carta, A Pilo, Fernanda Velluzzi, F Atzeni, I. Pelligra, Antonella Olivieri, R Cirillo, A Lai, G. Guaita, G. F. Bottazzo, G. Pinna, Stefano Mariotti, and Mariella Sorcini
Subjects: Adult, Adolescent, Endocrinology, Diabetes and Metabolism, Population, Pregnancy in Diabetics, Iodide Peroxidase, Thyroiditis, Islets of Langerhans, Endocrinology, Pregnancy, medicine, Humans, education, Autoantibodies, Autoimmune disease, Type 1 diabetes, education.field_of_study, business.industry, Incidence (epidemiology), Thyroid, Delivery, Obstetric, medicine.disease, Anti-thyroid autoantibodies, Diabetes, Gestational, Cross-Sectional Studies, medicine.anatomical_structure, Italy, Immunology, Postpartum thyroiditis, Female, business
Abstract: A high incidence of autoimmune Type 1 diabetes mellitus (DM) has been clearly established in Sardinia. Although systematic epidemiological studies are still not available, an increased prevalence of thyroid autoantibodies (ATA) has been documented in the Sardinian adult population as compared to other Italian regions, suggesting that thyroid autoimmune disease may also have increased. We carried out a preliminary study with the aim of determining the prevalence of serological markers of thyroid (anti-thyroperoxydase antibodies, TPOAb) and islet cell (ICA) autoimmunity in a large number (no.=2249) of sera obtained from cord-blood of Sardinian pregnant women at delivery. The prevalence of TPOAb was 11.9%, while ICA were detected in 59 cases (2.6%). A higher prevalence of TPOAb (6/17=35.3%) was found in sera with high ICA titers (or = 20 JDF-U), as compared to sera with low ICA titers (5-19 JDF-U) and to ICA-negative sera (3/42=7,1%; chi2=5.4, p=0.02 and 258/2190=11,8%; chi2=6.8, p=0.009 respectively). Fourteen women (all ICA-negative) were diabetic: 4 had Type 1 and 10 had gestational DM; due to the low number, no correlation could be established between DM type and TPOAb prevalence and/or titer. These preliminary data indicate that ATA are frequently observed in the general population of Sardinian pregnant women at term. As a consequence, even the frequency of postpartum thyroiditis is expected to be high. Although ATA were not increased in women with clinical overt diabetes, a higher prevalence of ATA was found in women with high titers of circulating ICA. Our results also confirm that Sardinia represents, perhaps for its peculiar genetic characteristics, an ideal place to study organ-specific autoimmunity.
Published: 2001
Full Text: View/download PDF

70. The usefulness of conventional and echo colour Doppler sonography in the differential diagnosis of toxic multinodular goitres

Author: S. Mariotti, M Loy, F Atzeni, Francesco Boi, Alessandra Serra, and M. Piga
Subjects: Adult, Male, endocrine system, medicine.medical_specialty, Adolescent, endocrine system diseases, Pertechnetate, Endocrinology, Diabetes and Metabolism, Graves' disease, Trab, Sensitivity and Specificity, Diagnosis, Differential, chemistry.chemical_compound, Endocrinology, Internal medicine, medicine, Humans, Euthyroid, Ultrasonography, Doppler, Color, Toxic multinodular goitre, Radionuclide Imaging, Aged, business.industry, Thyroiditis, Autoimmune, General Medicine, Middle Aged, Multinodular goitre, medicine.disease, Anti-thyroid autoantibodies, chemistry, Female, Differential diagnosis, business, Goiter, Nodular, Immunoglobulins, Thyroid-Stimulating
Abstract: OBJECTIVE: To assess the potential role of conventional sonography and colour flow Doppler (CFD) sonography (CFDS) in the differential diagnosis of toxic multinodular goitres. SUBJECTS AND METHODS: We investigated 55 patients with untreated hyperthyroidism (24 with typical toxic diffuse goitre of Graves' disease (Group A); 26 with multinodular goitre (Group B); and five with single toxic adenoma (Group C); 22 euthyroid subjects (12 with non-toxic multinodular goitre (Group D) and ten normal subjects (Group E)) were included as controls. In all cases free thyroxine, free tri-iodothyronine, TSH, TSH receptor antibodies (TRAb), anti-thyroperoxidase antibody, anti-thyroglobulin antibodies and anti-thyroid microsomal antibodies were determined and a [(99m)Tc]pertechnetate thyroid scan was performed. RESULTS: Patients with toxic multinodular goitre displayed two different CFDS patterns: 18 patients (Group B-1) had nodules with normal vascularity surrounded by diffuse parenchymal hypoechogenicity with markedly increased CFD signal and maximal peak systolic velocity (PSV) (a pattern similar to Group A patients with Graves' disease); eight patients (Group B-2) had increased intra- and perinodular CFD signal and PSV with normal extranodular vascularity (a pattern similar to that found in Group C patients with single toxic adenoma). Patients of Group B-1 showed a proportion of clinically evident thyroid ophthalmopathy, positive TRAb and other thyroid autoantibodies similar to that observed in Group A patients, while no evidence of thyroid autoimmunity was found in Group B-2. Sixteen out of 18 (89%) patients from Group B-1 displayed a scintiscan pattern of diffuse uneven radionuclide distribution, while seven out of eight (87.5%) of those from Group B-2 had localized uptake in multiple discrete nodules. Taken together, these data strongly suggest that Group B-1 mostly represents patients with the multinodular variant of Graves' disease, while Group B-2 represents patients with non-autoimmune toxic multinodular goitre. CONCLUSIONS: This study shows that combined conventional sonography and CFDS may easily distinguish nodular variants of Graves' disease from non-autoimmune forms of toxic multinodular goitre and confirms the clinical usefulness of this technique in the first-line evaluation of hyperthyroid patients.
Published: 2000
Full Text: View/download PDF

71. Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: Results of a community-based study in northwestern Sardinia

Author: F Atzeni, Pierluigi Cocco, Stefano Mariotti, Gl Mastinu, Andrea Loviselli, Alessandro Oppo, G Orgiana, Fernanda Velluzzi, Antonella Balestrieri, and Patrizia Farci
Subjects: Male, Endocrinology, Diabetes and Metabolism, Hepatitis C virus, Population, Prevalence, Hepacivirus, medicine.disease_cause, Iodide Peroxidase, Autoimmune Diseases, Serology, Immunoenzyme Techniques, Endocrinology, Risk Factors, Thyroid peroxidase, Humans, Medicine, Risk factor, education, Aged, Aged, 80 and over, Sex Characteristics, education.field_of_study, biology, business.industry, Age Factors, Hepatitis C, Hepatitis C Antibodies, Middle Aged, medicine.disease, Thyroid Diseases, Anti-thyroid autoantibodies, Italy, Immunology, biology.protein, Female, business
Abstract: To assess the relationship between serological markers of thyroid autoimmunity and chronic hepatitis C, we surveyed the general population of two villages in the region of Sardinia, Italy, where infection with hepatitis viruses is endemic and the prevalence of autoimmune diseases is elevated. A total of 1310 subjects aged 6-88 years (65% of the total resident population) participated in the survey, and 1233 (94%; 444 males and 789 females) agreed to provide a blood sample. Autoantibodies to thyroid peroxidase (anti-TPO) were measured by radioimmunoassay; antibodies to HCV (anti-HCV) by a third generation enzyme immunoassay and borderline positive results confirmed by recombinant immunoblot assay. For both anti-HCV and anti-TPO the age- and gender-standardized prevalence rates (SPR) were calculated and the significance of the association between the two antibodies tested by Yates corrected chi2 test. The overall SPR for anti-HCV was 50.7x10(-3) (86/1,233), similar between men [49.1x10(-3) (22/444)] and women [52.3x10(-3) (64/789)]. The overall SPR for anti-TPO was 136.9x10(-3) (204/1,233), and that among women [201x10(-3) (174/789)] was almost 3-fold that among men [71.6x10(-3) (30/444)]. A concurrent anti-HCV and anti-TPO positivity was found in a small minority of subjects [8/1,233 (0.65%)], all women aged 57-81 years. The SPR for the two concurrent events was 3.3x10(-3), which was not significantly different (Yates corrected chi2 test = 0.65) from that expected under the assumption of unrelated events. To explore whether HCV infection is a risk factor for anti-TPO positivity, we designed a case-control study with anti-TPO positive subjects as the cases, and anti-TPO negative subjects as the controls. The age- and gender-adjusted odd ratio (OR) was 0.4 (95% CI 0.2,0.7), indicating a negative association. In conclusion, no evidence for epidemiological association of circulating thyroid autoantibodies and antibodies to HCV was found. Our findings do not therefore support a pathogenetic link between HCV infection and thyroid autoimmunity.
Published: 1999
Full Text: View/download PDF

72. [Low back pain and fibromyalgia syndrome]

Author: F, Atzeni and P, Sarzi-Puttini
Subjects: Analgesics, Fibromyalgia, Anti-Inflammatory Agents, Non-Steroidal, Pain Perception, Comorbidity, Combined Modality Therapy, Antidepressive Agents, Risk Factors, Disease Progression, Prevalence, Humans, Stress, Mechanical, Chronic Pain, Low Back Pain, Bed Rest, Physical Therapy Modalities
Published: 2013

73. Tumor Necrosis Factor

Author: P. Sarzi-Puttini and F. Atzeni
Subjects: Pathogenesis, medicine.anatomical_structure, Cytokine, Osteoclast, medicine.medical_treatment, medicine, Cancer research, Interleukin, Tumor necrosis factor alpha, Biology, Receptor, Immune complex, Proinflammatory cytokine
Abstract: Tumor necrosis factor (TNF), a 17 kDa protein consisting of 157 amino acids, is a homotrimer in solution that is mainly produced by activated macrophages, T lymphocytes, and natural killer (NK) cells. Proinflammatory cytokines such as TNF and interleukin (IL)-1β play a key role in the pathogenesis of rheumatoid arthritis (RA). TNF has major effects on bone remodeling: it regulates the bone marrow levels of osteoclast precursors directly by upregulating c-fms expression, and activates osteoclasts by enhancing the signaling mechanisms of the receptor activator of NF-κB (RANK). It also plays an important role in controlling infection. The macrophage release of TNF seems to be crucial for the formation and maintenance of granulomas, and plays a critical role in defending intracellular organisms against invasion. TNF is also involved in leukocyte trafficking and immune complex (IC) clearance. The role of TNF in cancer is not fully known, but seems to be related to its different concentrations in the various stages of tumorigenesis. Large quantities are produced in the heart and, although not entirely clear, the mechanisms by which TNF mediates cardiac injury once again seem to depend on its levels. TNF promotes dyslipidemia and insulin resistance, both of which are traditional risk factors for atherosclerotic processes. All of the above makes it clear that TNF is a pleiotropic cytokine involved in multiple homeostatic and pathological mechanisms.
Published: 2013
Full Text: View/download PDF

74. Cardiovascular involvement in psoriatic arthritis

Author: F. Atzeni, M. Battellino, L. Boccassini, Antonio Marchesoni, V. De Gennaro Colonna, Simona Sitia, Livio Tomasoni, Maurizio Turiel, and Piercarlo Sarzi-Puttini
Subjects: lcsh:Internal medicine, medicine.medical_specialty, Heart Diseases, Inflammatory arthritis, Population, asymmetric dimethylarginine, lcsh:Medicine, Arthritis, Coronary Disease, Arginine, Gastroenterology, chemistry.chemical_compound, Psoriatic arthritis, Rheumatology, Coronary Circulation, Internal medicine, Psoriasis, medicine, Humans, risk factors, Endothelial dysfunction, Risk factor, lcsh:RC31-1245, education, Inflammation, psoriatic arthritis, education.field_of_study, Tumor Necrosis Factor-alpha, business.industry, Microcirculation, Arthritis, Psoriatic, lcsh:R, cardiovascular involvement, medicine.disease, chemistry, Antirheumatic Agents, Immunology, Cytokines, business, Asymmetric dimethylarginine
Abstract: Psoriasis is a chronic, genetically determined and immunomediated inflammatory skin disease that affects 2-3% of the Caucasian population. A considerable proportion of these patients develop a form of inflammatory arthritis known as psoriatic arthritis (PsA), although the prevalence of this has not been well defined. Patients with PsA have a higher mortality rate than the general population and the risk of mortality is related to disease severity at the time of presentation. Endothelial dysfunction and early atherosclerosis have been found in patients with PsA without any cardiovascular disease (CVD) risk factors, and experts believe that CVD is one of the leading causes of death, as it is in patients with rheumatoid arthritis (RA). Various disease-related mechanisms may be involved in the development of premature vascular damage in both cases, including an increased synthesis of proinflammatory mediators (such as cytokines, chemokines and adhesion molecules), autoantibodies against endothelial cell components, perturbations in T-cell subsets, genetic polymorphisms, hyperhomocysteinemia, oxidative stress, abnormal vascular repair, and iatrogenic factors. In a recent study of 22 patients with PsA without any signs of CVD, we found that the plasma concentration of asymmetric dimethylarginine (ADMA) levels were significantly high and coronary flow reserve (CFR) was significantly reduced. Moreover, there was a significant correlation between CFR and plasma ADMA levels in the PsA group. The significant correlation between the reduced CRF and increased ADMA levels suggests that, like patients with early RA, PsA patients suffer from endothelial dysfunction and impaired coronary microcirculation. Active PsA is a risk factor for CVD, and so PsA patients should be screened for subclinical forms of the disease and its risk factors, and an early treatment approach should be adopted.
Published: 2011
Full Text: View/download PDF

75. Which kind of exercise is best in fibromyalgia therapeutic programmes? A practical review

Author: M, Cazzola, F, Atzeni, F, Salaffi, S, Stisi, G, Cassisi, and P, Sarzi-Puttini
Subjects: Fibromyalgia, Treatment Outcome, Humans, Pain, Pain Management, Water, Resistance Training, Exercise, Exercise Therapy
Abstract: All of the specialists who deal in some way with fibromyalgia (FM) broadly agree that physical reconditioning programmes are useful, but it is not yet clear what type of physical activity is the most appropriate for different subsets of patients. The aim of this review was to examine the randomised controlled trials (RCTs) published between 1985 and August 2010 whose outcome measures indicate the effectiveness of different types of physical exercise (PE) on the main health domains affected by FM: pain, and physical and mental function. Studies that simultaneously used different types of PE or multimodal treatment strategies were excluded from the analysis, as were those in which the primary and secondary endpoints prevented any assessment of treatment efficacy in all three health domains. Twenty-seven studies were selected: 15 considered land-based physical aerobic exercise (PAE); seven exercises in water; and five muscle strengthening exercise (MSE). There was substantial uniformity in assessing the effectiveness of land- or water-based PAE and MSE in improving aerobic physical fitness (PF) and functional state. Water-based PAE offers some advantages over similarly intense land-based PAE in reducing spontaneous pain and improving depressive symptoms, but the data are insufficient to establish its overall superiority. Regardless of method, the latest findings concerning the neurophysiology of nociception indicate the fundamental importance of assigning workloads that do not exacerbate post-exercise pain.
Published: 2010

76. Health-related quality of life in fibromyalgia patients: a comparison with rheumatoid arthritis patients and the general population using the SF-36 health survey

Author: F, Salaffi, P, Sarzi-Puttini, R, Girolimetti, F, Atzeni, S, Gasparini, and W, Grassi
Subjects: Adult, Male, Analysis of Variance, Chi-Square Distribution, Fibromyalgia, Health Status, Middle Aged, Health Surveys, Severity of Illness Index, Arthritis, Rheumatoid, Cross-Sectional Studies, Mental Health, Surveys and Questionnaires, Quality of Life, Humans, Female, Aged, Pain Measurement
Abstract: To compare health-related quality of life (HRQL) in fibromyalgia (FM) patients with that of patients with rheumatoid arthritis (RA) and the general population, and investigate if the factors are associated with the greater impact of FM.This cross-sectional study involved 380 patients with FM, 693 patients with RA and 1579 healthy controls. HRQL was evaluated using the Medical Outcome Study Short-Form 36 (SF-36), and the measures included disease-related characteristics, demographic variables and comorbidities. S-scores were calculated for comparisons with the norm, and multivariate analyses were used to assess the relationships between HRQL and clinical and demographic variables.In comparison with the general population, the FM patients showed significant impairment in relation to all of the eight scales of the SF-36 (p0.0001), as well as the physical and mental component summary scores (PCS and MCS) (p0.0001). The mean PCS and MCS of the FM patients were 38.5 (SD=6.9) and 32.8 (SD=10.9), whereas those of the RA patients were 33.5 (SD=6.4) (p0.01) and 40.2 (SD=11.9) (p0.001). The dimensions typically affected by FM were vitality (s-score -1.61), mental health (s-score -1.46) and general health (s-score-1.47), whereas physical functioning (s-score-1.63) and role limitations due to physical function (s -score -0.94) were more impaired in the RA patients; the bodily pain scores were similar in the two groups. The PCS was lower than the MCS in the RA patients (s-scores -1.80 vs. -0.62), but the two scores were similar in the FM patients (s-scores -1.20 vs. -1.08). Multiple regression models showed that the physical component of the SF-36 was associated with widespread pain (the SAPS score) (p0.0001), educational level (p=0.0017), and the body mass index (p=0.007), and the mental component was associated with the widespread pain (p=0.0005), sleep abnormalities (p=0.0033), physical function (p=0.015), fatigue (p=0.029), gender (p=0.014) and a low educational level (p=0.0007).Patients with FM see the disease as having a worse health than RA patients and the general population, especially in terms of mental health.
Published: 2010

77. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis

Author: M, Turiel, L, Tomasoni, S, Sitia, S, Cicala, L, Gianturco, C, Ricci, F, Atzeni, V, De Gennaro Colonna, M, Longhi, and P, Sarzi-Puttini
Subjects: Adult, Male, Time Factors, Carotid Artery, Common, Ischemic heart disease, Antibodies, Monoclonal, Humanized, Arginine, Vascular biology, Severity of Illness Index, Antibodies, Arthritis, Rheumatoid, Rheumatoid, Coronary Circulation, Vascular, Monoclonal, Interventional cardiology, Lipids disorder/atherosclerosis, Adalimumab, Aged, Antibodies, Monoclonal, Antirheumatic Agents, Biomarkers, Case-Control Studies, Coronary Vessels, Echocardiography, Doppler, Endothelium, Vascular, Female, Humans, Italy, Methotrexate, Microcirculation, Middle Aged, Treatment Outcome, Pharmacology, Cardiology and Cardiovascular Medicine, Pharmacology (medical), Endothelium, Humanized, Arthritis, Doppler, Common, Echocardiography, Carotid Artery
Abstract: Rheumatoid arthritis (RA) is associated with enhanced atherosclerosis and impaired endothelial function early after the onset of the disease and cardiovascular (CV) disease represents one of the leading causes of morbidity and mortality. It is well known that disease modifying antirheumatic drugs (DMARDs) are able to improve the course of the disease and the quality of life of these patients, but little is known about the effects of DMARDs on CV risk and endothelial dysfunction. Our goal was to examine the effects of long-term therapy with DMARDs on endothelial function and disease activity in early RA (ERA). Twenty-five ERA patients (mean age 52 ± 14.6 years, disease duration 6.24 ± 4.10 months) without evidence of CV involvement were evaluated for disease activity score (DAS-28), 2D-echo derived coronary flow reserve (CFR), common carotid intima-media thickness (IMT) and plasma asymmetric dimethylarginine (ADMA) levels at baseline and after 18 months of treatment with DMARDs (10 patients with methotrexate and 10 with adalimumab). DMARDs significantly reduced DAS-28 (6.0 ± 0.8 vs. 2.0 ± 0.7; P0.0001) and improved CFR (2.4 ± 0.2 vs. 2.7 ± 0.5; P0.01). Common carotid IMT and plasma ADMA levels did not show significant changes. The present study shows that DMARDs, beyond the well known antiphlogistic effects, are able to improve coronary microcirculation without a direct effect on IMT and ADMA, clinical markers of atherosclerosis. Treatment strategies in ERA patients with high inflammatory activity must be monitored to identify beneficial effects on preclinical markers of vascular function.
Published: 2010

78. Bleomycin-Induced Scleroderma: Report of a Case with a Chronic Course Rather Than the Typical Acute/Subacute Self-Limiting Form

Author: P. Nurchis, M Aledda, Giuseppe Passiu, Alberto Cauli, P. Garau, M Laudadio, Alessandra Vacca, Alessandro Mathieu, G. Dessole, F Atzeni, and G. Sanna
Subjects: Adult, medicine.medical_specialty, Pathology, medicine.medical_treatment, Disease, Bleomycin, Scleroderma, Lesion, Scleroderma, Localized, chemistry.chemical_compound, Rheumatology, Internal medicine, medicine, Humans, Family history, Chemotherapy, Antibiotics, Antineoplastic, integumentary system, business.industry, Remission Induction, General Medicine, medicine.disease, Connective tissue disease, Dermatology, chemistry, Chronic Disease, Female, medicine.symptom, business
Abstract: We report a case of bleomycin-induced scleroderma in a 35-year-old woman treated with chemotherapy for Hodgkin's disease. Approximately 6 months after the first chemotherapy cycle, the patient developed skin sclerosis in both arms. The lesion showed no signs of spontaneous clinical amelioration and treatment with steroids was unsuccessful. A partial remission of the skin sclerosis was instead obtained by the administration of D-penicillamine. A family history revealed other cases of autoimmune diseases and HLA typing showed the presence of antigens associated with scleroderma. The association between bleomycin therapy and scleroderma is discussed.
Published: 1999
Full Text: View/download PDF

79. Fibromyalgia: who should reshape the pain perception of these patients?

Author: P, Sarzi-Puttini, F, Atzeni, S, Stisi, and M, Cazzola
Subjects: Fibromyalgia, Humans, Pain, Pain Management, Perception
Published: 2008

80. Autoimmune diseases and infections: controversial issues

Author: P, Baio, A, Brucato, D, Buskila, M E, Gershwin, D, Giacomazzi, L R, Lopez, R, Luzzati, E, Matsuura, C, Selmi, P, Sarzi-Puttini, and F, Atzeni
Subjects: Humans, Infections, Autoimmune Diseases
Abstract: The etiology and pathogenesis of certain types of disease remain controversial and stand like a bridge that crosses infectious, autoimmune and autoinflammatory pathways. Infection, for example, may initiate a disease, although it is the genetic regulation in the host, the interplay between virus or bacteria persistence and autoimmunity that produces the later phases of disease, the antigenic determinants responsible for inducing autoimmune disease, and the pathogenetic effector mechanisms. Infections agents cause pericarditis, but in 85% of cases it is "idiopathic". It has also been shown that persistent Clamydia pneumoniae, Porphyromonas gingivalis, and Helicobacter pylori infections cause host immunity and promote atherogenesis. A number of infectious agents have been suggested as potential triggers for primary biliary cirrhosis. Infections and vaccinations have also been linked to the pathogenesis of fibromyalgia syndrome, a common, chronic syndrome of widespread pain. Many factors are also responsible for fever of unknown origin such as: infections, autoimmunity disease, etc. However, it is difficult to determine a direct correlation between the infections agents in such a large group of diseases. The aim of this review is to analyze some of the controversies about the role of infections in autoimmune diseases.
Published: 2008

81. Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporin A

Author: F, Atzeni, P, Sarzi-Puttini, F, Capsoni, L, Vulpio, and M, Carrabba
Subjects: Adult, Treatment Outcome, Dose-Response Relationship, Drug, Cyclosporine, Humans, Lupus Erythematosus, Systemic, Female, Infusions, Intravenous, Red-Cell Aplasia, Pure, Risk Assessment, Severity of Illness Index, Drug Administration Schedule, Follow-Up Studies
Abstract: We report a patient with longstanding systemic lupus erythematosus (SLE) who developed pure red cell aplasia (PRCA). This condition is rare in connective tissue diseases and is reported in 32 previous cases of SLE in literature. Our patient recovered, apparently in response to treatment with high dosage of corticosteroids, but relapse occurred when the prednisone dosage was tapered down to 10 mg/day. The patient was successfully treated with cyclosporin A with no recurrence of the disease in the last 2 years.
Published: 2004

82. Validation of an Italian version of the Fibromyalgia Impact Questionnaire (FIQ-I)

Author: P, Sarzi-Puttini, F, Atzeni, T, Fiorini, B, Panni, G, Randisi, M, Turiel, and M, Carrabba
Subjects: Adult, Male, Fibromyalgia, Reproducibility of Results, Middle Aged, Sensitivity and Specificity, Severity of Illness Index, Disability Evaluation, Italy, Sickness Impact Profile, Surveys and Questionnaires, Activities of Daily Living, Quality of Life, Humans, Female, Translations, Aged
Abstract: To validate a translated Italian version of the Fibromyalgia Impact Questionnaire (FIQ).The Italian version of the FIQ was administered to 50 patients affected by fibromyalgia (FM) (48 patients filled out the questionnaire again 10 days later) together with the Italian version of the Stanford Health Assessment Questionnaire (HAQ), the Medical Outcomes Survey Short Form-36 (SF-36), and a tender point count (TPC) obtained by summing the score (0-3) of each tender point tested by thumb palpation. All patients were asked about the severity of pain today (10 cm visual analog scale) and the duration of symptoms. Test-retest reliability was assessed using Spearman correlations. Internal consistency was evaluated with Cronbach's alpha of reliability. Construct validity of the FIQ was evaluated by correlations between the HAQ and subscales of the SF-36 as well as the TPC.The mean duration of symptoms was 6.5 years and the mean age of the participants was 57.4 years. Test-retest reliability was between 0.74 and 0.95 for physical functioning as well as for the total FIQ and other components. Internal consistency was 0.90 for the overall FIQ. Significant correlations were obtained between the FIQ items, the HAQ and the SF-36.The Italian FIQ is a reliable and valid instrument for detecting and measuring functional disability and health status in Italian patients with FM.
Published: 2003

83. [Cardiovascular risk factors in systemic lupus erythematosus and in antiphospholipid syndrome]

Author: P, Sarzi-Puttini, F, Atzeni, and M, Carrabba
Subjects: Arteriosclerosis, Cardiovascular Diseases, Risk Factors, Hyperhomocysteinemia, Humans, Lupus Erythematosus, Systemic, Antiphospholipid Syndrome
Abstract: Systemic Lupus Erythematosus (SLE) is an autoimmune disorder affecting multiple organ systems. Treatment of the disease has contributed dramatically in the long-term survival of the patients and now SLE has become a chronic inflammatory disorder. Present data suggest 5, 10 and 20-year survival rates of 93%, 85% and 68% respectively. Accelerated atherosclerosis and early coronary artery disease have become important causes of death and hospitalisation in SLE patients. Many cardiovascular risk factors can be considered: disease activity (particularly kidney involvement), sedentary life (in nearly 70% of the patients), hyperlipidemia, antiphospholipid antibodies, serum homocysteine and many others. Although traditional risk factors are operative in patients with SLE, the risk for myocardial infarction was increased 8.3 folds after controlling these factors in a study, suggesting that SLE itself was the strongest risk factor for cardiovascular disease. Lipid abnormalities may play a major role in increasing cardiovascular risk in SLE patients who are characterized by elevated triglycerides, very low-density lipoprotein cholesterol (VLDL-C), reduced levels of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A-1. Anticardioli-pin antibodies may influence lipid levels in SLE; in particular SLE patients with IgG anticardiolipin antibodies had significantly lower HDL-C compared with patients with no anticardiolipin antibodies. Elevation of serum homocysteine is observed in 15% of SLE patients and is significantly associated with the development of stroke and arterial thrombotic events. The antiphospholipid syndrome (APS) is an acquired thrombotic disorder characterised by recurrent venous or arterial thrombosis or recurrent miscarriages, or both, associated with the presence in the serum of IgG or IgM anticardiolipin antibodies (aCL) and/or lupus anticoagulant (LAC). APS may occur as a primary disorder (PAPS) or associated with connective tissue diseases, mainly systemic lupus erythematosus (secondary APS). Primary and secondary APS are both associated with a significant increase of cardiovascular risk.
Published: 2003

84. High prevalence of male hypogonadism and sexual dysfunction in long-term clinically stable heart transplantation recipients

Author: F Atzeni, Pierpaolo Orrù, Maurizio Porcu, Stefano Mariotti, Alessandro Oppo, Stefano Serra, Marco Corda, Emmanuele Serra, A. Cappai, and Luigi Minerba
Subjects: Heart transplantation, Pediatrics, medicine.medical_specialty, High prevalence, Male hypogonadism, business.industry, medicine.medical_treatment, Urology, Follow up studies, Testosterone (patch), medicine.disease, Erectile dysfunction, Sexual dysfunction, medicine, Young adult, medicine.symptom, Cardiology and Cardiovascular Medicine, business
Published: 2012
Full Text: View/download PDF

85. The Sardinian Autoimmunity Study: 3. Studies on circulating antithyroid antibodies in Sardinian schoolchildren: relationship to goiter prevalence and thyroid function

Author: Marco Songini, F Atzeni, Fernanda Velluzzi, Antonella Balestrieri, G. Secci, Enio Martino, Ma Cambosu, A. Taberlet, Lucia Grasso, Gian Franco Bottazzo, P Mossa, Andrea Loviselli, and Stefano Mariotti
Subjects: Male, endocrine system, medicine.medical_specialty, Goiter, endocrine system diseases, Adolescent, Endocrinology, Diabetes and Metabolism, Thyroid Gland, chemistry.chemical_element, Physiology, Autoimmunity, Iodine, Endocrinology, Age Distribution, Hypothyroidism, Thyroid peroxidase, Internal medicine, medicine, Prevalence, Humans, Sex Distribution, Child, Autoantibodies, biology, business.industry, Thyroid, Autoantibody, medicine.disease, Iodine deficiency, Thyroid Diseases, Anti-thyroid autoantibodies, medicine.anatomical_structure, chemistry, Italy, biology.protein, Female, Thyroid function, business
Abstract: The relationship among iodine intake, goiter prevalence, and thyroid autoimmunity remains controversial. In the present article, we report the prevalence of antithyroid antibodies (ATA) in relation to iodine intake, frequency of goiter, and thyroid function in a large group of Sardinian schoolchildren living in areas with borderline iodine sufficiency, or mild to moderate iodine deficiency. A total of 8,040 schoolchildren (4,194 males, 3,846 females, ages 6-15 years) from 29 communities were examined between 1986-1994. Thyroid size was assessed by palpation, according to the Pan American Health Organization (PAHO) criteria. In all cases antimicrosomal (MAb) or antithyroid peroxidase antibodies (TPOAb) and thyrotropin (TSH) were assayed. Urinary iodine was determined in a subgroup of 820 children. ATA was detected in 235 (2.92%) sera (88 males, 2.12%; 147 females, 3.82%; chi2 = 20.41, p0.0001). ATA prevalence ranged between 0.0%-7.3% in the 29 communities without any geographical correlation with goiter prevalence and urinary iodine excretion. However, ATA was more frequently detected in goitrous children, especially in females. The presence of ATA was not age-dependent in males, whereas a significant increase of ATA was observed in females older than 11 years of age. Seventy-seven (0.96%) children showed borderline to slightly increased serum TSH (5.2-32 mU/L). Increased serum TSH concentration was more frequently found in children with ATA, especially at higher titers. In summary, our study in Sardinian schoolchildren indicates: (1) ATA display geographical heterogeneity, which seems to be unrelated to goiter prevalence and/or to iodine supply; (2) ATA are more frequently detected in females older than 11 years of age, suggesting that puberty has a role in determining the predominance in females of thyroid autoimmunity; (3) although most goitrous children are ATA-negative, the prevalence of ATA is increased in children with enlarged glands; (4) ATA is associated with an increased prevalence of subclinical hypothyroidism.
Published: 2001

86. Thyroid and celiac disease: clinical, serological, and echographic study

Author: F Velluzzi, A Caradonna, M F Boy, M A Pinna, R Cabula, M A Lai, E Piras, G Corda, P Mossa, F Atzeni, A Loviselli, P Usai, and S Mariotti
Subjects: Adult, Aged, 80 and over, Male, Thyroid Hormones, Hepatology, Genotype, Gastroenterology, Thyrotropin, Middle Aged, Iodide Peroxidase, Thyroid Diseases, Gliadin, HLA-DQ alpha-Chains, Immunoglobulin A, Celiac Disease, Reticulin, Italy, HLA-DQ Antigens, Immunoglobulin G, HLA-DQ beta-Chains, Humans, Female, Aged, Autoantibodies, Ultrasonography
Abstract: We sought to reevaluate the prevalence of thyroid dysfunction and thyroid autoimmunity in 47 patients with celiac disease; 91 healthy subjects were studied as controls. Both patients and controls were from Sardinia, Italy.Diagnosis of celiac disease was made on the basis of clinical history, presence of positive antigliadin IgA (AGA-A) and IgG (AGA-G) antibodies, antireticulin antibodies (ARA), antiendomysium antibodies (EMA), and was confirmed by jejunal biopsy. HLA class II typing for DQB1 and DQA1 alleles was performed in 36/47 celiac patients. Thyroid was evaluated by palpation and echography; serum free thyroid hormones (FT4, FT3), thyrotropic hormone (TSH), and antithyroid peroxidase autoantibodies (anti-TPO) were assayed by radioimmunoassays.The prevalence of anti-TPO was higher in celiac patients (29.7%) than in healthy controls (9.6%) (p0.001) and thyroid echography frequently displayed (42.5%) a hypoechogenic pattern. Five anti-TPO-positive celiac patients were hypothyroid (two overt, three subclinical). A higher but not significantly different prevalence of anti-TPO (3/7 = 42.8%) was found in celiac patients displaying the DQB1*0502 genotype, when compared with the remaining patients (8/29 = 27.6%).An elevated prevalence of clinical and subclinical autoimmune thyroid autoimmunity was found in Sardinian celiac patients, especially in those displaying the DQB1*0502 genotype; this finding could be related to a particular genetic background of the Sardinian population.
Published: 1998

87. FRI0255 The 158vv fcgamma receptor 3a genotype is associated with response to rituximab in rheumatoid arthritis: results of an italian multicentre study

Author: L. Quartuccio, M. Fabris, E. Pontarini, S. Salvin, A. Zabotti, M. Benucci, M. Manfredi, D. Biasi, V. Ravagnani, F. Atzeni, P. Sarzi Puttini, P. Morassi, F. Fischetti, P. Tomietto, L. Bazzichi, M. Saracco, R. Pellerito, M. Cimmino, F. Schiavon, V. Carraro, A. Semeraro, R. Caporali, L. Cavagna, R. Bortolotti, G. Paolazzi, M. Govoni, S. Bombardieri, and S. De Vita
Subjects: Rheumatology, Immunology, Immunology and Allergy, General Biochemistry, Genetics and Molecular Biology
Published: 2013
Full Text: View/download PDF

88. Lack of association of the 463 G/A myeloperoxidase promoter polymorphism with Behcets disease in Italian patients.

Author: F. Atzeni, L. Boiardi, B. Casali, E. Farnetti, P. Sarzi-Puttini, N. Pipitone, I. Olivieri, F. Cantini, F. Salvi, R. La Corte, G. Triolo, D. Filippini, G. Paolazzi, and C. Salvarani
Subjects: *GENETICS of disease susceptibility, *GENETIC polymorphisms, *BEHCET'S disease, *POPULATION genetics
Abstract: Objective. To investigate potential associations between the −463 G/A myeloperoxidase (MPO) promoter polymorphism and susceptibility to, and clinical expression of, Behçets disease (BD). Methods. One hundred and seventy-five Italian patients who satisfied the International Study Group criteria for BD and 235 healthy age- and sex-matched blood donors were genotyped for the −463 G/A promoter polymorphism of the MPO gene by molecular methods. The patients were subgrouped according to the presence or absence of clinical manifestations. Results. The distribution of allele and genotype frequencies of the MPO −463A/G polymorphism did not differ significantly between the BD patients and the healthy controls. Carriers of the −463 A allele (A/A or A/G) [odds ratio (OR) 0.7, 95% confidence interval (CI) 0.5–1.1] and homozygosity for A allele (OR 0.3, 95% CI 0.1–1.3) were less frequent among BD patients than among the controls, but the difference was not statistically significant. No significant associations were found when BD patients with and those without clinical manifestations were compared. Conclusion. Our data suggest that the −463 G/A promoter polymorphism of the MPO gene is not associated with susceptibility to, and clinical expression of, BD in Italian patients. [ABSTRACT FROM AUTHOR]
Published: 2007
Full Text: View/download PDF

89. The TTTT BLyS promoter haplotype associates with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to TNF blockers

Author: Fabris, M, Quartuccio, L, Vital, E, Pontarini, E, Salvin, S, Fabro, C, Zabotti, A, Benucci, M, Manfredi, M, Ravagnani, V, Biasi, D, Atzeni, F, Sarzi Puttini, P, Morassi, P, Fischetti, F, Bazzicchi, L, Saracco, M, Pellerito, R, Cimmino, M, Carraro, V, Semeraro, A, Schiavon, F, Caporali, R, Bortolotti, R, Govoni, Marcello, Fogolari, F, Tonutti, E, Bombardieri, S, Emery, P, De Vita, S., M., Fabri, L., Quartuccio, E., Vital, E., Pontarini, S., Salvin, C., Fabro, A., Zabotti, M., Benucci, M., Manfredi, V., Ravagnani, D., Biasi, F., Atzeni, P., Sarzi Puttini, P., Morassi, Fischetti, Fabio, L., Bazzicchi, M., Saracco, R., Pellerito, M., Cimmino, V., Carraro, A., Semeraro, F., Schiavon, R., Caporali, R., Bortolotti, M., Govoni, F., Fogolari, E., Tonutti, S., Bombardieri, P., Emery, and S. D., Vita
Subjects: rheumatoid arthritis, "B lymphocyte, BLyS, rituximab, polymorphism, synovitis", therapeutic response, biologic therapy, TTTT BLys promoter, rheumatoid arthriti
Abstract: OBJECTIVE.: To investigate the polymorphisms in the promoter region of B-Lymphocyte Stimulator (BLyS) gene as markers of response to rituximab (RTX) in rheumatoid arthritis (RA). METHODS.: The study was first conducted in 152 Italian RA patients and then replicated in 117 patients (73 Italian, 44 British). Response to therapy (DAS28; EULAR criteria) was evaluated at months +4 and +6 after RTX and patients were classified according to the best response they showed during this period. BLyS promoter polymorphisms were analyzed by RFLP-PCR, BLyS promoter haplotypes by Expectation-Maximization algorithm and BLyS serum levels by ELISA. RESULTS.: The TTTT BLyS promoter haplotype appeared significantly associated with response to RTX only in the subset of seropositive (rheumatoid factor and/or anti-CCP positive) patients. The replication series confirmed that this association was limited to seropositive RA patients who previously failed anti-tumor necrosis factor (TNF) agents. In the whole series of anti-TNF-failure seropositive patients, TTTT-carrying patients were more prevalent in good responders (18/43; 41.9\%) than in moderate (20/83; 24.1\%) and in non responders (1/21; 4.8\%), (good vs. non responders: OR 14.4, 95\%CI:1.77-117.39, p=0.0028). Furthermore, the TTTT BLyS haplotype was selected as an independent marker of good response to RTX by multivariate analysis (good vs. non responders: OR 16.2, 95\% CI 1.7-152.5; p=0.01; good vs. moderate plus non responders: OR 3.05, 95\%CI:1.19-7.82, p=0.02). The relationship between BLyS polymorphims and BLyS serum levels remained unclear. CONCLUSION.: BLyS promoter genotyping may be suitable to identify seropositive RA patients who may show good response to RTX after anti-TNF agents failure.
Published: 2012

90. The holistic management of peripheral spondyloarthritis: focus on articular involvement in patients with inflammatory bowel disease.

Author: Lubrano E, Armuzzi A, Scriffignano S, Felice C, Perrotta FM, Venerito V, Del Vescovo S, Ramonda R, Cassone G, Atzeni F, Caporali R, Conti F, Gremese E, Iannone F, Sebastiani M, and Favalli EG
Abstract: Objective: To provide a comprehensive overview of peripheral spondyloarthritis (pSpA), focusing specifically on its occurrence and management in patients with inflammatory bowel disease (IBD)., Methods: An exhaustive literature search was conducted in PubMed, Embase, Cochrane Database of Systematic Reviews, and Google Scholar to identify relevant studies on pSpA in IBD patients. Titles, abstracts, and full-text articles were screened for relevance. Data on study design, patient characteristics, diagnostic criteria, main findings, and conclusions were extracted from selected articles. Study quality was assessed using appropriate checklists. Information was synthesized narratively to summarize current understanding., Results: pSpA is the most common extraintestinal manifestation in IBD, with a median prevalence of 16%. It worsens quality of life and requires collaboration between gastroenterologists and rheumatologists for optimal diagnosis and treatment. Several "red flags" guide appropriate specialist referral of IBD patients with suspected pSpA. Once the diagnosis is confirmed, the choice of therapy depends on IBD phenotype and patterns of articular/axial involvement. Anti-tumor necrosis factor (TNF) drugs are first-line biologics, with interleukin (IL)-12/23 and IL-23 inhibitors as alternatives for anti-TNF failure. Small molecules like apremilast and Janus kinase inhibitors also have utility. Recommended treatment algorithms exist, but more randomized controlled trials are needed., Conclusions: Early identification of pSpA is crucial in IBD patients to enable timely intervention, prevent structural damage, and minimize disability. A multidisciplinary, holistic approach addressing musculoskeletal and extra-musculoskeletal manifestations is key to optimal patient outcomes.
Published: 2024
Full Text: View/download PDF

91. Adherence to the 2019 ESC/EAS guidelines for dyslipidaemia management in a large rheumatoid arthritis cohort: Data from the CORDIS Study Group of the Italian Society of Rheumatology.

Author: Cacciapaglia F, Spinelli FR, Erre GL, Piga M, Sakellariou G, Manfredi A, Fornaro M, Viapiana O, Perniola S, Gremese E, Atzeni F, and Bartoloni E
Abstract: Background/aim: Lipid-lowering therapy prescription is low in rheumatoid arthritis (RA) patients, often not achieving lipid threshold target despite treatment. However, evidence derives from small, monocentric cohorts. We assessed adherence to lipid-lowering treatment for primary cardiovascular (CV) prevention in a RA cohort according to international guidelines., Methods: A cross-sectional analysis of an Italian RA cohort was performed. Disease-related features and traditional CV risk factors were collected. The 10-year CV risk was estimated by Systematic COronary Risk Evaluation 2 (SCORE-2) algorithm. The primary preventive dyslipidaemia strategy was assessed according to 2019 European Society of Cardiology/European Atherosclerosis Society guidelines., Results: 1.133 RA patients (78.2% female, aged 60.6±10.2 years) free from CV events were included. According to SCORE-2, 42.9% of patients were at moderate risk (1-5-%), 33.3% at high risk (5-10%) and 23.7% at very high risk (>10%). In the whole cohort, 12.9% of patients with <5%, 23.6% with 5-10% and 32.3% with >10% risk were on statin, respectively (p<0.001). According to 2019 ESC/EAS guidelines, 51.5% of patients had LDL-c at target. Among patients with LDL-c not at target, 76% were not on lipid-lowering treatment. At multivariate analysis, patients with higher CV risk had significantly lower probability of LDL-c at target., Conclusion: In a wide Italian RA cohort, more than 50% of patients had high or very high CV risk. In these, lipid-lowering treatment prescription is suboptimal leading to not achievement of LDL-c target. Physicians should improve lipid screening and primary prevention therapy to reduce CV risk and improve CV comorbidity in RA patients., Competing Interests: Conflict of interest None declared., (Copyright © 2024. Published by Elsevier B.V.)
Published: 2024
Full Text: View/download PDF

92. Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registry.

Author: Chimenti MS, Fatica M, Fornaro M, Lopalco G, Corrado A, Rotondo C, Semeraro A, Colella S, Praino E, Gorla R, Bazzani C, Babaglioni G, Foti R, Floris A, Frediani B, Atzeni F, Conti F, Cauli A, Caporali R, Iannone F, and Guiducci S
Subjects: Humans, Male, Female, Middle Aged, Treatment Outcome, Prospective Studies, Italy, Adult, Remission Induction, Antirheumatic Agents therapeutic use, Time Factors, Aged, Arthritis, Psoriatic drug therapy, Arthritis, Psoriatic diagnosis, Registries, Antibodies, Monoclonal, Humanized therapeutic use, Severity of Illness Index
Abstract: Objectives: We aimed to evaluate ixekizumab (IXE) effectiveness, drug survival and clinical response predictors in moderate-severe psoriatic arthritis (PsA) patients in different clinical scenarios., Methods: This was a multicentre real-life observational study based on Gruppo Italiano Studio Early Arthritis (GISEA) registry of IXE treatment in PsA patients (January 2019-June 2023). Data were collected at baseline and every six months., Results: 223 PsA outpatients were included. Statistically significant improvement was observed after 6 (T6), 12 (T12) and 24 (T24) months of therapy for tender and swollen joint count (TJC and SJC), Visual Analogue Scale (VAS)-pain and Disease Activity in PSoriatic Arthritis (DAPSA) score. DAPSA remission was reached at T12 in 22% and at T24 in 18.5% of patients. At baseline, higher fibromyalgia and combination therapy with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) in females with respect to males and higher Psoriasis Area Severity Index (PASI) in males than in females were observed. Therapeutic effectiveness showed in males higher DAPSA and VAS-pain reduction, higher percentage of males in DAPSA remission/low disease activity (LDA) at T6, and higher ∆PASI at T6 and T12 than in female patients. At multivariate analysis, male sex was predictive for treatment response at T6 [p=0.02, odds ratio (OR) 2.49 (95% confidence interval 1.11-5.54)], while it lost significance at T12., Conclusions: IXE effectiveness was highlighted after 6 months at both joint and skin levels and lasted up to 24 months in different clinical scenarios, making IXE effective in the complexity of managing PsA in a real-life setting.
Published: 2024
Full Text: View/download PDF

93. Pulmonary Progressive Fibrosis in Rheumatoid Arthritis and Primary Sjogren Syndrome: Similarities and Differences.

Author: Manfredi A, Venerito V, Cazzato M, Sambataro G, Zanini U, Gozzi F, Gentileschi S, Canofari C, Atzeni F, Cassone G, Iannone F, Laurino E, Vancheri C, Luppi F, Cerri S, and Sebastiani M
Abstract: Background: Progressive pulmonary fibrosis (PPF) has been associated with a worse prognosis, even when interstitial lung disease (ILD) is related to rheumatic diseases. Since many differences are detectable among rheumatic diseases in prevalence and features of ILD, we aimed to investigate features of PPF in different rheumatic diseases, namely rheumatoid arthritis (RA) and primary Sjogren's syndrome (pSS). Methods: In an Italian multicentre cross-sectional study, consecutive pSS or RA patients with a diagnosis of ILD from at least two years were enrolled. For each patient, demographic, clinical, and serological data, other than chest high-resolution computed tomography and lung function tests, were recorded at the enrolment and after 2 years. Results : Among 232 patients, namely 156 RA-ILD and 76 pSS-ILD, a PPF was recorded in 38.8% of cases, without differences between the two diseases. Analysing patients with a PPF, usual interstitial pneumonia was significantly more frequent in RA than pSS (71.4% and 44.4%, respectively; p = 0.019), while ILD preceded the diagnosis of the rheumatic disease in 29.1% of RA and 89.5% of pSS ( p < 0.001). Finally, RA patients were significantly younger than pSS at the diagnosis of the rheumatic disease ( p < 0.001). Conclusions: In conclusion, although there is a similar prevalence of PPF in RA-ILD and pSS-ILD, we demonstrated for the first time that the two conditions differ in terms of radiological patterns and demographic and clinical features, suggesting that specific factors related to such diseases might influence the lung involvement over time. Prospective studies could investigate if these specificities could induce different responses to the treatment.
Published: 2024
Full Text: View/download PDF

94. Cardiovascular disease risk in systemic lupus erythematous: Certainties and controversies.

Author: Atzeni F, Rodríguez-Pintó I, and Cervera R
Subjects: Humans, Risk Factors, Heart Disease Risk Factors, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic immunology, Cardiovascular Diseases etiology, Cardiovascular Diseases diagnosis, Cardiovascular Diseases immunology, Cardiovascular Diseases epidemiology
Abstract: Patients with systemic lupus erythematosus (SLE) experience greater cardiovascular morbidity and mortality compared to the general population. It is known that endothelial dysfunction, an early indicator of atherosclerosis development, can arise even without the presence of conventional cardiovascular risk factors. In fact, the risk factors contributing to cardiovascular disease can be classified into traditional risk factors and those uniquely associated with SLE such as disease activity, autoantibodies, etc.Furthermore, the pathogenesis of cardiovascular disease in SLE is linked to the activation of both the innate and adaptive immune systems. Given these findings, it is essential for clinicians to acknowledge the heightened CVD risk in SLE patients, perform comprehensive screenings for cardiovascular risk factors, and implement aggressive treatment strategies for those who exhibit signs of clinical CVD. The aim of this review is to summarize the findings on cardiovascular disease in SLE and to examine potential screening and therapeutic strategies for clinical practice., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
Published: 2024
Full Text: View/download PDF

95. Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort.

Author: Ramonda R, Lorenzin M, Chimenti MS, Atzeni F, Semeraro A, D'Angelo S, Selmi C, Ortolan A, Marchesoni A, Manara M, Luchetti Gentiloni MM, Santo L, Salvarani C, Cauli A, Rossini M, Amato G, Cozzi G, Scagnellato L, Ferraioli M, Carriero A, Fracassi E, Giorgio F, Doria A, Foti R, and Carletto A
Subjects: Humans, Male, Female, Middle Aged, Italy epidemiology, Treatment Outcome, Adult, Cohort Studies, Aged, Antirheumatic Agents therapeutic use, Antirheumatic Agents adverse effects, Follow-Up Studies, Prospective Studies, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Arthritis, Psoriatic drug therapy
Abstract: Objectives: to evaluate over a 48-month follow-up period the: 1) long-term effectiveness and safety; 2) drug retention rate (DRR); 3) impact of comorbidities and bDMARDs line on MDA and DAPSA remission/low disease activity (LDA) of secukinumab in a multicenter Italian cohort of PsA patients., Methods: Consecutive PsA patients receiving secukinumab were followed prospectively in Italian centers between 2016 and 2023. Disease characteristics, previous/ongoing treatments, comorbidities and follow-up duration were recorded. Treatment response was evaluated at 6 and 12 months after initiation, and every year up to 48 months (T48). DRR was assessed according to clinical and demographic features, comorbidities and bDMARDs line. Adverse events (AE) were recorded., Results: Six hundred eighty-five patients [42.5% male] were enrolled; 32.9% naïve received secukinumab; 74.2% had ≥ 1 comorbidity. Overall, secukinumab yielded improved outcomes at T48: naïve maintained lower disease activity vs. non-naïve [DAPSA 4.0 (1.4-8.1) vs. 6.0 (2.2-10.4);p = 0.04]; 76.9% naïve and 66.2% non-naïve achieved MDA; MDA no comorbidities vs. 1-3 comorbidities 78.8% vs. 73.3% (p < 0.05), and MDA no comorbidities vs. > 3 comorbidities 78.8% vs. 48.7% (p < 0.001). DAPSA-REM and DAPSA-LDA rates were higher in naïve patients, albeit similar between those without comorbidities vs. 1-3 comorbidities, and slightly lower in those with > 3 comorbidities. Treatment was discontinued in 233 patients due to loss of effectiveness, and in 41 due to AE. The overall DRR at T48 was 66%, with differences according to bDMARDs line (p < 0.001), use of combined csDMARDs (p = 0.016), BMI (p = 0.037) and mono/oligoarthritis vs. polyarthritis (p = 0.012)., Conclusions: Secukinumab proved safe and effective, and patients achieved sustained remission with a notable drug retention rate at 4 years., (© 2024. The Author(s).)
Published: 2024
Full Text: View/download PDF

96. Geographical disparities in fibromyalgia severity: An Italian study.

Author: Di Carlo M, Farah S, Atzeni F, Alciati A, Di Franco M, Iannuccelli C, Bazzichi L, Bianchi G, Giovale M, Tirri R, Guiducci S, Guggino G, Franceschini F, Foti R, Lo Gullo A, Biasi G, Gremese E, Dagna L, Tirri E, Giacomelli R, Batticiotto A, Cutolo M, Sarzi-Puttini P, and Salaffi F
Abstract: Background: Geographic origin may represent a variable capable of influencing health status. This study aims to investigate the presence of differences of disease severity in Italian patients with fibromyalgia from different macro-regions., Methods: This retrospective, cross-sectional study involved patients included in the Italian Fibromyalgia Registry. Three geographical macro-regions were identified, comprising patients from Northern Italy, Central Italy and Southern Italy. Clinical differences (evaluated through PolySymptomatic Distress Scale [PSD], revised Fibromyalgia Impact Questionnaire [FIQR] and modified Fibromyalgia Assessment Status [FASmod]) among the geographical macro-regions were studied using one-way analysis of variance (ANOVA) and the Scheffé's test., Results: A total of 6095 patients (5719 females and 376 males) were included, with 1957 from Northern Italy, 2979 from Central Italy and 1159 from Southern Italy. All studied clinical indices showed a trend indicative of greater disease severity in Southern Italy, followed by Northern Italy and then Central Italy (mean values for PSD: 19.97 ± 6.20 in Northern Italy, 18.61 ± 7.12 in Central Italy, 23.01 ± 5.66 in Souther Italy). These differences were statistically significant for the overall scores of all studied indices, evaluated with ANOVA (all p < 0.001) and in the head to head comparisons, evaluted with Scheffé's test., Conclusions: Geographic background is significantly associated with variations in the severity of fibromyalgia in Italian patients., Significance Statement: This is the first study to demonstrate geographical origin-dependent intra-national differences in the severity of fibromyalgia. The results confirm the necessity of considering fibromyalgia within the context of the biopsychosocial model and of implementing healthcare policies targeted towards the most underserved regions., (© 2024 The Author(s). European Journal of Pain published by John Wiley & Sons Ltd on behalf of European Pain Federation ‐ EFIC ®.)
Published: 2024
Full Text: View/download PDF

97. Interstitial lung disease in rheumatic diseases: an update of the 2018 review.

Author: Atzeni F, Alciati A, Gozza F, Masala IF, Siragusano C, and Pipitone N
Abstract: Introduction: Interstitial lung disease (ILD) is a potential severe complication of various rheumatic diseases, typically connective tissue diseases (CTD), associated with significant morbidity and mortality. ILD may occur during the course of the disease but may also be its first manifestation. Several cell types are involved in ILD's pathogenesis, and if not controlled, pulmonary inflammation may lead to pulmonary fibrosis., Areas Covered: We searched PubMed, Medline, and the Cochrane Library for papers published between 1995 and February 2017 in the first version, and between 2017 and April 2023 using combinations of words. The most frequent systemic rheumatic diseases associated with ILD are systemic sclerosis (SSc), rheumatoid arthritis (RA), and idiopathic inflammatory myositis. Treatment and monitoring guidelines are still lacking, and current treatment strategies have been extrapolated from the literature on SSc and established treatments for non-pulmonary systemic rheumatic manifestations., Expert Opinion: Given the complexity of diagnosis and the paucity of treatment trials, managing CTD patients with ILD is challenging. It requires the skills of multidisciplinary CTD-ILD clinics including at least rheumatologists and lung specialists.
Published: 2024
Full Text: View/download PDF

98. Sex and gender differences in comorbidities in spondyloarthritis: a focus on psoriatic arthritis.

Author: Atzeni F, Siragusano C, Tropea A, and Alciati A
Subjects: Humans, Female, Male, Sex Factors, Spondylarthritis epidemiology, Spondylarthritis complications, Risk Factors, Sex Characteristics, Heart Disease Risk Factors, Antirheumatic Agents therapeutic use, Arthritis, Psoriatic epidemiology, Cardiovascular Diseases epidemiology, Cardiovascular Diseases etiology, Comorbidity
Abstract: Objective: Spondyloarthritis is a family of inflammatory diseases subdivided into those affecting the spine, called axial spondyloarthritis, and those involving peripheral joints, such as psoriatic arthritis (PsA). Several studies have reported differences in clinical manifestations, outcomes, and treatment responses between male and female PsA patients. The aim of our review was to evaluate if differences may also be identified in the context of cardiovascular (CV) risk factors and diseases., Methods: Patients with PsA have a higher CV risk than the general population. The increased CV risk associated with PsA is likely caused by the complex interplay of traditional CV risk factors, chronic systemic inflammation, and side effects related to the use of certain anti-rheumatic drugs., Results: Sex differences in CV risk factors in PsA patients, according to several studies, are controversial. However, the few studies that reported sex-stratified estimates did not find differences in the risk of stroke and myocardial infarction between sexes. The same also holds true for CV mortality. These mixed results may be related to the different study designs and case definitions, as well as genetic and geographical variability across the investigated populations., Conclusions: In conclusion, our review suggests that the evaluation of sex-gender aspects of CV comorbidities in PsA should be a central step in the context of personalized medicine in order to prevent and treat properly associated comorbidities.
Published: 2024
Full Text: View/download PDF

99. Preferences for diagnostic pathways and treatment choice in systemic lupus erythematosus: a patient-based discrete choice experiment.

Author: Quartuccio L, Piga M, Atzeni F, Callori M, Doria A, Emmi G, Franceschini F, Gerosa M, Mosca M, Pasqualetti P, Pelissero R, Sebastiani GD, Conti F, and Govoni M
Abstract: Objectives: Starting from the unmet need of early diagnosis and treatment in systemic lupus erythematosus (SLE), the study aims to explore patient preferences in diagnostic pathways and treatment modalities. It seeks to integrate clinical priorities with patient perspectives, providing an optimal approach to SLE treatment that remains uncertain., Methods: A discrete choice experiment (DCE) has been conducted to investigate whether patient preferences align while maintaining consistent attributes and levels, providing a direct assessment of relative preferences and hypothetical treatment approaches in SLE., Results: DCE results demonstrated that obtaining an early diagnosis is the most crucial attribute for patients. Additionally, a multidisciplinary care team, capable of enhancing clinical outcomes and patient satisfaction, is essential, along with a clinical centre conveniently located within 30 minutes of the patient's home. Lastly, patients prefer the opportunity to reduce glucocorticoid to a dosage ≤5 mg/day, and eventually discontinue, aligning with the new EULAR recommendations, and favour oral and subcutaneous routes of administration for new course of treatment., Conclusions: Patient preferences contribute to enhancing the care pathway for SLE by optimising disease management, with a focus on multidisciplinarity and psychological support.
Published: 2024
Full Text: View/download PDF

100. Diagnostic pathway and treatment preferences for systemic lupus erythematosus: a physician-based discrete choice experiment.

Author: Piga M, Quartuccio L, Atzeni F, Doria A, Emmi G, Franceschini F, Gerosa M, Mosca M, Pasqualetti P, Sebastiani GD, Conti F, and Govoni M
Abstract: Objectives: To assess physicians' preferences on diagnostic pathways and treatment priorities for systemic lupus erythematosus (SLE) using a discrete choice experiment (DCE)., Methods: A board of 11 SLE experts and a DCE expert statistician defined informative profiles of diagnostic pathways, pharmacological therapies, and two distinct profiles of mild-moderate and severe SLE. An independent panel of 115 clinicians involved in SLE management was invited to participate. Parameter estimates from the model were interpreted as relative preference weights (PWs). The mean PWs were used to calculate each attribute's relative importance (RI)., Results: 95 clinicians (57% females, 71% rheumatologists) completed the DCEs. The DCEs could not identify a hierarchy of importance among diagnostic pathway attributes. Nevertheless, "referral time to a rheumatologist" was considered more important for mild-moderate (RI=25%) and severe (RI=20%) SLE. Among the therapeutic attributes, the effect on organ damage progression after 12 months showed the highest preference for mild-moderate (RI=35%) and severe (RI=41%) SLE patients, followed by reduction in disease activity levels (max RI=19%) and glucocorticoid dose (max RI=13%) after six months. Reducing prednisone dose below 5 mg/day scored higher utility levels for mild-moderate (PW=66.1) than severe (PW=14.2) SLE. Administration route, action rapidity, patient-global assessment, and serious infection risk showed lesser relevance (RI 7-8%). No distinctions were found among subgroups categorised by the clinicians' areas of expertise., Conclusions: These DCEs highlight a high degree of awareness among lupus-treating physicians, with no differences across medical specialties, of the unmet need for early diagnosis and prevention of damage accrual in SLE management.
Published: 2024
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

613 results on '"F. Atzeni"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources